{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:04:23Z","timestamp":1789945463872,"version":"4.0.1"},"reference-count":271,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06203-1","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:56:24Z","timestamp":1789944984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the BACE1\u2013GSK-3\u03b2 Signaling Axis in Alzheimer\u2019s Disease: From Molecular Crosstalk to Nanotechnology-Based Translational Strategies"],"prefix":"10.1007","volume":"63","author":[{"given":"Anitha","family":"Marimuthu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu Tanya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaramakrishnan","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Thaggikuppe","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"6203_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.742408","author":"MB Abubakar","year":"2022","unstructured":"Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH et al (2022) Alzheimer\u2019s disease: an update and insights into pathophysiology. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.742408","journal-title":"Front Aging Neurosci"},{"key":"6203_CR2","unstructured":"WHO (2026) Dementia. World Health Organization, Fact Sheets. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia (Accessed 31 January 2026)"},{"key":"6203_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101580","volume":"51","author":"A Nandi","year":"2022","unstructured":"Nandi A, Counts N, Chen S, Seligman B, Tortorice D, Vigo D, Bloom DE (2022) Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: a value of statistical life approach. eClinicalMedicine 51:101580. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101580","journal-title":"eClinicalMedicine"},{"issue":"11","key":"6203_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112167","volume":"11","author":"MC Jurc\u0103u","year":"2022","unstructured":"Jurc\u0103u MC, Andronie-Cioara FL, Jurc\u0103u A, Marcu F, \u0162i\u021b DM, Pa\u0219cal\u0103u N, Nistor-Cseppent\u00f6 DC (2022) The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer\u2019s disease: therapeutic implications and future perspectives. Antioxidants (Basel) 11(11):2167. https:\/\/doi.org\/10.3390\/antiox11112167","journal-title":"Antioxidants (Basel)"},{"key":"6203_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-981-99-6038-5_2","volume-title":"Natural product-based synthetic drug molecules in Alzheimer\u2019s disease","author":"SA Fathima","year":"2023","unstructured":"Fathima SA, Maurya R, Naqvi S (2023) Oxidative stress and metals in Alzheimer\u2019s disease. Natural product-based synthetic drug molecules in Alzheimer\u2019s disease. Springer Nature Singapore, Singapore, pp 17\u201341. https:\/\/doi.org\/10.1007\/978-981-99-6038-5_2"},{"key":"6203_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4103\/1673-5374.320970","volume":"17","author":"Y Ju","year":"2022","unstructured":"Ju Y, Tam K (2022) Pathological mechanisms and therapeutic strategies for Alzheimer\u2019s disease. Neural Regen Res 17:543\u2013549. https:\/\/doi.org\/10.4103\/1673-5374.320970","journal-title":"Neural Regen Res"},{"key":"6203_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112753","volume":"10","author":"N Papadopoulos","year":"2022","unstructured":"Papadopoulos N, Suelves N, Perrin F, Vadukul DM, Vrancx C, Constantinescu SN, Kienlen-Campard P (2022) Structural determinant of \u03b2-amyloid formation: from transmembrane protein dimerization to \u03b2-amyloid aggregates. Biomedicines 10:2753. https:\/\/doi.org\/10.3390\/biomedicines10112753","journal-title":"Biomedicines"},{"key":"6203_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101500","volume":"7","author":"NJ Joshi","year":"2024","unstructured":"Joshi NJ, Reddy ARS (2024) Navigating the GSK-3\u03b2 inhibitors as versatile multi-target drug ligands in Alzheimer\u2019s disease intervention \u2013 a comprehensive review. Results Chem 7:101500. https:\/\/doi.org\/10.1016\/j.rechem.2024.101500","journal-title":"Results Chem"},{"key":"6203_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen ZR, Huang JB, Yang SL, Hong FF (2022) Role of cholinergic signaling in Alzheimer\u2019s disease. Molecules 27:1816. https:\/\/doi.org\/10.3390\/molecules27061816","journal-title":"Molecules"},{"key":"6203_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111677","volume":"22","author":"GA Czapski","year":"2021","unstructured":"Czapski GA, Strosznajder JB (2021) Glutamate and GABA in microglia-neuron cross-talk in Alzheimer\u2019s disease. Int J Mol Sci 22:11677. https:\/\/doi.org\/10.3390\/ijms222111677","journal-title":"Int J Mol Sci"},{"key":"6203_CR11","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1038\/s41401-025-01576-w","volume":"46","author":"W Wu","year":"2025","unstructured":"Wu W, Gong X, Qin Z, Wang Y (2025) Molecular mechanisms of excitotoxicity and their relevance to the pathogenesis of neurodegenerative diseases\u2014an update. Acta Pharmacol Sin 46:3129\u20133142. https:\/\/doi.org\/10.1038\/s41401-025-01576-w","journal-title":"Acta Pharmacol Sin"},{"issue":"Suppl 1","key":"6203_CR12","doi-asserted-by":"publisher","first-page":"45S","DOI":"10.2967\/jnumed.121.263200","volume":"63","author":"JC Masdeu","year":"2022","unstructured":"Masdeu JC, Pascual B, Fujita M (2022) Imaging neuroinflammation in neurodegenerative disorders. J Nucl Med 63(Suppl 1):45S-52S. https:\/\/doi.org\/10.2967\/jnumed.121.263200","journal-title":"J Nucl Med"},{"key":"6203_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.13419","volume":"327","author":"B Tastan","year":"2024","unstructured":"Tastan B, Heneka MT (2024) The impact of neuroinflammation on neuronal integrity. Immunol Rev 327:8\u201332. https:\/\/doi.org\/10.1111\/imr.13419","journal-title":"Immunol Rev"},{"key":"6203_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907804","volume":"13","author":"VTA Tran","year":"2022","unstructured":"Tran VTA, Lee LP, Cho H (2022) Neuroinflammation in neurodegeneration via microbial infections. Front Immunol 13:907804. https:\/\/doi.org\/10.3389\/fimmu.2022.907804","journal-title":"Front Immunol"},{"key":"6203_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043754","volume":"24","author":"J Andrade-Guerrero","year":"2023","unstructured":"Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, Vargas-Rodr\u00edguez I, Cadena-Su\u00e1rez AR, S\u00e1nchez-Garibay C et al (2023) Alzheimer\u2019s disease: an updated overview of its genetics. Int J Mol Sci 24:3754. https:\/\/doi.org\/10.3390\/ijms24043754","journal-title":"Int J Mol Sci"},{"key":"6203_CR16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40266-023-01065-x","volume":"40","author":"N Bittner","year":"2023","unstructured":"Bittner N, Funk CSM, Schmidt A, Bermpohl F, Brandl EJ, Algharably EEA et al (2023) Psychiatric adverse events of acetylcholinesterase inhibitors in Alzheimer\u2019s disease and Parkinson\u2019s dementia: systematic review and meta-analysis. Drugs Aging 40:953\u2013964. https:\/\/doi.org\/10.1007\/s40266-023-01065-x","journal-title":"Drugs Aging"},{"key":"6203_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1201\/9781032676555-4","volume-title":"Zebrafish models of neurodegenerative disorders","author":"N Tekin","year":"2025","unstructured":"Tekin N, \u00c7ulpan Y, G\u00fclhan R (2025) Pharmacotherapy of neurodegenerative diseases. Zebrafish models of neurodegenerative disorders. CRC Press, Boca Raton, pp 57\u201368. https:\/\/doi.org\/10.1201\/9781032676555-4"},{"key":"6203_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","volume":"28","author":"W Wu","year":"2023","unstructured":"Wu W, Ji Y, Wang Z, Wu X, Li J, Gu F et al (2023) The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res 28:544. https:\/\/doi.org\/10.1186\/s40001-023-01512-w","journal-title":"Eur J Med Res"},{"key":"6203_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.862369","volume":"13","author":"CG Withington","year":"2022","unstructured":"Withington CG, Turner RS (2022) Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease. Front Neurol 13:862369. https:\/\/doi.org\/10.3389\/fneur.2022.862369","journal-title":"Front Neurol"},{"key":"6203_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ et al (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther 13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8","journal-title":"Alzheimers Res Ther"},{"issue":"4 Suppl","key":"6203_CR21","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.jalz.2010.08.148","volume":"6","author":"F Martenyi","year":"2010","unstructured":"Martenyi F et al (2010) Central and peripheral pharmacokinetic and pharmacodynamic effects of the \u03b2-site APP cleavage enzyme (BACE1) inhibitor LY2811376 in humans. Alzheimers Dement 6(4 Suppl):S512. https:\/\/doi.org\/10.1016\/j.jalz.2010.08.148","journal-title":"Alzheimers Dement"},{"key":"6203_CR22","unstructured":"A Safety Study of LY2811376 Single Doses in Healthy Subjects (2009) Eli Lilly and Company. ClinicalTrials.gov Identifier: NCT00838084. https:\/\/clinicaltrials.gov\/study\/NCT00838084 (Accessed 10 November 2025)"},{"key":"6203_CR23","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1021\/jm011020u","volume":"45","author":"A Martinez","year":"2002","unstructured":"Martinez A, Alonso M, Castro A, P\u00e9rez C, Moreno FJ (2002) First non-ATP competitive glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer\u2019s disease. J Med Chem 45:1292\u20131299. https:\/\/doi.org\/10.1021\/jm011020u","journal-title":"J Med Chem"},{"key":"6203_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1074\/jbc.M111.306472","volume":"287","author":"JM Dom\u00ednguez","year":"2012","unstructured":"Dom\u00ednguez JM, Fuertes A, Orozco L, del Monte-Mill\u00e1n M, Delgado E, Medina M (2012) Evidence for irreversible inhibition of glycogen synthase kinase-3\u03b2 by tideglusib. J Biol Chem 287:893\u2013904. https:\/\/doi.org\/10.1074\/jbc.M111.306472","journal-title":"J Biol Chem"},{"key":"6203_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"L Seren\u00f3","year":"2009","unstructured":"Seren\u00f3 L et al (2009) A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis 35:359\u2013367. https:\/\/doi.org\/10.1016\/j.nbd.2009.05.025","journal-title":"Neurobiol Dis"},{"key":"6203_CR26","doi-asserted-by":"publisher","first-page":"12311","DOI":"10.3390\/ijms252212311","volume":"25","author":"MG Sighencea","year":"2024","unstructured":"Sighencea MG et al (2024) From fundamentals to innovation in Alzheimer\u2019s disease: molecular findings and revolutionary therapies. Int J Mol Sci 25:12311. https:\/\/doi.org\/10.3390\/ijms252212311","journal-title":"Int J Mol Sci"},{"key":"6203_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-3311-3_1","volume-title":"Methods in molecular biology","author":"V Kumar","year":"2023","unstructured":"Kumar V, Roy K (2023) Recent progress in the treatment strategies for Alzheimer\u2019s disease. Methods in molecular biology. Humana, New York, pp 3\u201347. https:\/\/doi.org\/10.1007\/978-1-0716-3311-3_1"},{"key":"6203_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100163","volume":"12","author":"D Angioni","year":"2025","unstructured":"Angioni D et al (2025) Challenges and opportunities for novel combination therapies in Alzheimer\u2019s disease: a report from the EU\/US CTAD Task Force. J Prev Alzheimers Dis 12:100163. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100163","journal-title":"J Prev Alzheimers Dis"},{"key":"6203_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914794","volume":"24","author":"KS Orobets","year":"2023","unstructured":"Orobets KS, Karamyshev AL (2023) Amyloid precursor protein and Alzheimer\u2019s disease. Int J Mol Sci 24:14794. https:\/\/doi.org\/10.3390\/ijms241914794","journal-title":"Int J Mol Sci"},{"key":"6203_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/1568026623666221228140450","volume":"23","author":"SM Munj","year":"2023","unstructured":"Munj SM, Patil PB (2023) Drug discovery to drug development of BACE1 inhibitor as antialzheimer\u2019s: a review. Curr Top Med Chem 23:77\u201397. https:\/\/doi.org\/10.2174\/1568026623666221228140450","journal-title":"Curr Top Med Chem"},{"key":"6203_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13430","volume":"23","author":"HA Taylor","year":"2022","unstructured":"Taylor HA, Przemylska L, Clavane EM, Meakin PJ (2022) BACE1: more than just a \u03b2-secretase. Obes Rev 23:e13430. https:\/\/doi.org\/10.1111\/obr.13430","journal-title":"Obes Rev"},{"key":"6203_CR32","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H et al (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26:5481\u20135503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0","journal-title":"Mol Psychiatry"},{"key":"6203_CR33","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1042\/BCJ20240056","volume":"481","author":"J Wang","year":"2024","unstructured":"Wang J, Fourriere L, Gleeson PA (2024) Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer\u2019s disease mutations. Biochem J 481:1297\u20131325. https:\/\/doi.org\/10.1042\/BCJ20240056","journal-title":"Biochem J"},{"key":"6203_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bbrc.2020.11.092","volume":"534","author":"L Gu","year":"2021","unstructured":"Gu L, Guo Z (2021) Alzheimer\u2019s A\u03b242 and A\u03b240 form mixed oligomers with direct molecular interactions. Biochem Biophys Res Commun 534:292\u2013296. https:\/\/doi.org\/10.1016\/j.bbrc.2020.11.092","journal-title":"Biochem Biophys Res Commun"},{"key":"6203_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5483\/BMBRep.2024-0044","volume":"57","author":"D Im","year":"2024","unstructured":"Im D, Choi TS (2024) Distinctive contribution of two additional residues in protein aggregation of A\u03b242 and A\u03b240 isoforms. BMB Rep 57:263\u2013272. https:\/\/doi.org\/10.5483\/BMBRep.2024-0044","journal-title":"BMB Rep"},{"key":"6203_CR36","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1021\/jacsau.2c00668","volume":"3","author":"D Im","year":"2023","unstructured":"Im D et al (2023) Decoding the roles of amyloid-\u03b2 (1\u201342)\u2019s key oligomerization domains toward designing epitope-specific aggregation inhibitors. JACS Au 3:1065\u20131075. https:\/\/doi.org\/10.1021\/jacsau.2c00668","journal-title":"JACS Au"},{"key":"6203_CR37","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1021\/bi00069a001","volume":"32","author":"JT Jarrett","year":"1993","unstructured":"Jarrett JT, Berger EP, Lansbury PT (1993) The carboxy terminus of the \u03b2-amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer\u2019s disease. Biochemistry 32:4693\u20134697. https:\/\/doi.org\/10.1021\/bi00069a001","journal-title":"Biochemistry"},{"key":"6203_CR38","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108591","volume":"41","author":"K Konstantoulea","year":"2022","unstructured":"Konstantoulea K et al (2022) Heterotypic amyloid \u03b2 interactions facilitate amyloid assembly and modify amyloid structure. EMBO J 41:EMBJ2021108591. https:\/\/doi.org\/10.15252\/embj.2021108591","journal-title":"EMBO J"},{"key":"6203_CR39","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1021\/acschemneuro.2c00358","volume":"13","author":"SG Itoh","year":"2022","unstructured":"Itoh SG, Yagi-Utsumi M, Kato K, Okumura H (2022) Key residue for aggregation of amyloid-\u03b2 peptides. ACS Chem Neurosci 13:3139\u20133151. https:\/\/doi.org\/10.1021\/acschemneuro.2c00358","journal-title":"ACS Chem Neurosci"},{"key":"6203_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/jnr.10859","volume":"75","author":"R Liu","year":"2004","unstructured":"Liu R, McAllister C, Lyubchenko Y, Sierks MR (2004) Residues 17\u201320 and 30\u201335 of \u03b2-amyloid play critical roles in aggregation. J Neurosci Res 75:162\u2013171. https:\/\/doi.org\/10.1002\/jnr.10859","journal-title":"J Neurosci Res"},{"key":"6203_CR41","doi-asserted-by":"publisher","first-page":"13882","DOI":"10.1021\/jacs.6b06000","volume":"138","author":"NL Truex","year":"2016","unstructured":"Truex NL, Wang Y, Nowick JS (2016) Assembly of peptides derived from \u03b2-sheet regions of \u03b2-amyloid. J Am Chem Soc 138:13882\u201313890. https:\/\/doi.org\/10.1021\/jacs.6b06000","journal-title":"J Am Chem Soc"},{"key":"6203_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.abm7285","volume":"375","author":"Y Yang","year":"2022","unstructured":"Yang Y et al (2022) Cryo-EM structures of amyloid-\u03b242 filaments from human brains. Science 375:167\u2013172. https:\/\/doi.org\/10.1126\/science.abm7285","journal-title":"Science"},{"key":"6203_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12683-8","volume":"10","author":"M Kollmer","year":"2019","unstructured":"Kollmer M et al (2019) Cryo-EM structure and polymorphism of A\u03b2 amyloid fibrils purified from Alzheimer\u2019s brain tissue. Nat Commun 10:4760. https:\/\/doi.org\/10.1038\/s41467-019-12683-8","journal-title":"Nat Commun"},{"key":"6203_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1126\/science.aao2825","volume":"358","author":"L Gremer","year":"2017","unstructured":"Gremer L et al (2017) Fibril structure of amyloid-\u03b2(1\u201342) by cryo-electron microscopy. Science 358:116\u2013119. https:\/\/doi.org\/10.1126\/science.aao2825","journal-title":"Science"},{"key":"6203_CR45","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00210-024-03500-1","volume":"398","author":"D Karati","year":"2025","unstructured":"Karati D et al (2025) Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 398:2319\u20132342. https:\/\/doi.org\/10.1007\/s00210-024-03500-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"6203_CR46","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.2174\/1389557522666220420094317","volume":"22","author":"N Chauhan","year":"2022","unstructured":"Chauhan N et al (2022) GSK-3\u03b2 and its inhibitors in Alzheimer\u2019s disease: a recent update. Mini Rev Med Chem 22:2881\u20132895. https:\/\/doi.org\/10.2174\/1389557522666220420094317","journal-title":"Mini Rev Med Chem"},{"key":"6203_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.34172\/apb.2023.071","volume":"13","author":"SR Shri","year":"2023","unstructured":"Shri SR, Manandhar S, Nayak Y, Pai KSR (2023) Role of GSK-3\u03b2 inhibitors: new promises and opportunities for Alzheimer\u2019s disease. Adv Pharm Bull 13:688\u2013700. https:\/\/doi.org\/10.34172\/apb.2023.071","journal-title":"Adv Pharm Bull"},{"key":"6203_CR48","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16635","volume":"11","author":"S Lai","year":"2023","unstructured":"Lai S, Wang P, Gong J, Zhang S (2023) New insights into the role of GSK-3\u03b2 in the brain: from neurodegenerative disease to tumorigenesis. PeerJ 11:e16635. https:\/\/doi.org\/10.7717\/peerj.16635","journal-title":"PeerJ"},{"key":"6203_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040721","volume":"10","author":"CL Sayas","year":"2021","unstructured":"Sayas CL, \u00c1vila J (2021) GSK-3 and tau: a key duet in Alzheimer\u2019s disease. Cells 10:721. https:\/\/doi.org\/10.3390\/cells10040721","journal-title":"Cells"},{"key":"6203_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-981-32-9358-8_2","volume-title":"Neurofibrillary tangles","author":"M Hasegawa","year":"2019","unstructured":"Hasegawa M (2019) Structure of NFT: biochemical approach. Neurofibrillary tangles. Springer, Singapore, pp 23\u201334. https:\/\/doi.org\/10.1007\/978-981-32-9358-8_2"},{"key":"6203_CR51","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.str.2024.12.017","volume":"33","author":"K Acosta","year":"2025","unstructured":"Acosta K, Brue CR, Holubovska P, Kim HJ, Mayne L, Murakami K, Rhoades E (2025) Structural insights into the role of the proline rich region in tau function. Structure 33:465-474.e8. https:\/\/doi.org\/10.1016\/j.str.2024.12.017","journal-title":"Structure"},{"issue":"1","key":"6203_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41467-023-36572-3","volume":"14","author":"V Mullapudi","year":"2023","unstructured":"Mullapudi V et al (2023) Network of hotspot interactions cluster tau amyloid folds. Nat Commun 14:895. https:\/\/doi.org\/10.1038\/s41467-023-36572-3","journal-title":"Nat Commun"},{"key":"6203_CR53","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1073\/pnas.97.10.5129","volume":"97","author":"M von Bergen","year":"2000","unstructured":"von Bergen M et al (2000) Assembly of \u03c4 protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming \u03b2 structure. Proc Natl Acad Sci U S A 97:5129\u20135134. https:\/\/doi.org\/10.1073\/pnas.97.10.5129","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6203_CR54","doi-asserted-by":"publisher","first-page":"48165","DOI":"10.1074\/jbc.M105196200","volume":"276","author":"M von Bergen","year":"2001","unstructured":"von Bergen M et al (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local \u03b2-structure. J Biol Chem 276:48165\u201348174. https:\/\/doi.org\/10.1074\/jbc.M105196200","journal-title":"J Biol Chem"},{"key":"6203_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nchem.2889","volume":"10","author":"PM Seidler","year":"2018","unstructured":"Seidler PM et al (2018) Structure-based inhibitors of tau aggregation. Nat Chem 10:170\u2013176. https:\/\/doi.org\/10.1038\/nchem.2889","journal-title":"Nat Chem"},{"key":"6203_CR56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jb\/mvp181","volume":"147","author":"C Nishiura","year":"2010","unstructured":"Nishiura C et al (2010) Importance of Tyr310 residue in the third repeat of microtubule binding domain for filament formation of tau protein. J Biochem 147:405\u2013414. https:\/\/doi.org\/10.1093\/jb\/mvp181","journal-title":"J Biochem"},{"key":"6203_CR57","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1016\/j.febslet.2010.09.012","volume":"584","author":"K Naruto","year":"2010","unstructured":"Naruto K et al (2010) Interplay between I308 and Y310 residues in the third repeat of microtubule-binding domain is essential for tau filament formation. FEBS Lett 584:4233\u20134236. https:\/\/doi.org\/10.1016\/j.febslet.2010.09.012","journal-title":"FEBS Lett"},{"key":"6203_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108843","volume":"34","author":"Y Carlomagno","year":"2021","unstructured":"Carlomagno Y et al (2021) The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. Cell Rep 34:108843. https:\/\/doi.org\/10.1016\/j.celrep.2021.108843","journal-title":"Cell Rep"},{"key":"6203_CR59","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jsps.2022.10.004","volume":"30","author":"HA Alhazmi","year":"2022","unstructured":"Alhazmi HA, Albratty M (2022) An update on the novel and approved drugs for Alzheimer disease. Saudi Pharm J 30:1755\u20131764. https:\/\/doi.org\/10.1016\/j.jsps.2022.10.004","journal-title":"Saudi Pharm J"},{"key":"6203_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112296","volume":"14","author":"D Nunes","year":"2022","unstructured":"Nunes D, Loureiro JA, Pereira MC (2022) Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimer\u2019s drugs. Pharmaceutics 14:2296. https:\/\/doi.org\/10.3390\/pharmaceutics14112296","journal-title":"Pharmaceutics"},{"key":"6203_CR61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/13543776.2021.1874344","volume":"31","author":"M Bortolami","year":"2021","unstructured":"Bortolami M et al (2021) Acetylcholinesterase inhibitors for the treatment of Alzheimer\u2019s disease \u2013 a patent review (2016\u2013present). Expert Opin Ther Pat 31:399\u2013420. https:\/\/doi.org\/10.1080\/13543776.2021.1874344","journal-title":"Expert Opin Ther Pat"},{"key":"6203_CR62","doi-asserted-by":"publisher","DOI":"10.12775\/JEHS.2025.77.57093","volume":"77","author":"D Rehan","year":"2025","unstructured":"Rehan D et al (2025) Advancing Alzheimer\u2019s diagnosis: the role of AI \u2013 a review. J Educ Health Sport 77:57093. https:\/\/doi.org\/10.12775\/JEHS.2025.77.57093","journal-title":"J Educ Health Sport"},{"key":"6203_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29235744","volume":"29","author":"N Puranik","year":"2024","unstructured":"Puranik N, Song M (2024) Glutamate: molecular mechanisms and signaling pathway in Alzheimer\u2019s disease, a potential therapeutic target. Molecules 29:5744. https:\/\/doi.org\/10.3390\/molecules29235744","journal-title":"Molecules"},{"key":"6203_CR64","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12035-020-02116-9","volume":"58","author":"MS Uddin","year":"2021","unstructured":"Uddin MS et al (2021) Multi-target drug candidates for multifactorial Alzheimer\u2019s disease: AChE and NMDAR as molecular targets. Mol Neurobiol 58:281\u2013303. https:\/\/doi.org\/10.1007\/s12035-020-02116-9","journal-title":"Mol Neurobiol"},{"key":"6203_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.757515","volume":"14","author":"PP Guan","year":"2021","unstructured":"Guan PP, Cao LL, Yang Y, Wang P (2021) Calcium ions aggravate Alzheimer\u2019s disease through the aberrant activation of neuronal networks, leading to synaptic and cognitive deficits. Front Mol Neurosci 14:757515. https:\/\/doi.org\/10.3389\/fnmol.2021.757515","journal-title":"Front Mol Neurosci"},{"key":"6203_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-56015-1_195-1","volume-title":"NeuroPsychopharmacotherapy","author":"J Benninghoff","year":"2022","unstructured":"Benninghoff J, Perneczky R (2022) Anti-dementia medications and anti-Alzheimer\u2019s disease drugs: side effects, contraindications, and interactions. NeuroPsychopharmacotherapy. Springer International Publishing, Cham, pp 1\u201310. https:\/\/doi.org\/10.1007\/978-3-319-56015-1_195-1"},{"key":"6203_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213954","volume":"23","author":"E Passeri","year":"2022","unstructured":"Passeri E et al (2022) Alzheimer\u2019s disease: treatment strategies and their limitations. Int J Mol Sci 23:13954. https:\/\/doi.org\/10.3390\/ijms232213954","journal-title":"Int J Mol Sci"},{"key":"6203_CR68","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1038\/s41380-022-01565-z","volume":"27","author":"L Peng","year":"2022","unstructured":"Peng L, Bestard-Lorigados I, Song W (2022) The synapse as a treatment avenue for Alzheimer\u2019s disease. Mol Psychiatry 27:2940\u20132949. https:\/\/doi.org\/10.1038\/s41380-022-01565-z","journal-title":"Mol Psychiatry"},{"issue":"Suppl 1","key":"6203_CR69","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.3233\/JAD-240146","volume":"101","author":"JRM Coimbra","year":"2024","unstructured":"Coimbra JRM, Resende R, Cust\u00f3dio JBA, Salvador JAR, Santos AE (2024) BACE1 inhibitors for Alzheimer\u2019s disease: current challenges and future perspectives. J Alzheimers Dis 101(Suppl 1):S53\u2013S78. https:\/\/doi.org\/10.3233\/JAD-240146","journal-title":"J Alzheimers Dis"},{"key":"6203_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo3610","volume":"8","author":"N Singh","year":"2022","unstructured":"Singh N, Das B, Zhou J, Hu X, Yan R (2022) Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improves cognitive performance. Sci Adv 8:eabo3610. https:\/\/doi.org\/10.1126\/sciadv.abo3610","journal-title":"Sci Adv"},{"key":"6203_CR71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14656566.2024.2438317","volume":"26","author":"D Antony","year":"2025","unstructured":"Antony D et al (2025) Recent advances in Alzheimer\u2019s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein. Expert Opin Pharmacother 26:63\u201373. https:\/\/doi.org\/10.1080\/14656566.2024.2438317","journal-title":"Expert Opin Pharmacother"},{"key":"6203_CR72","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/ph19010138","volume":"19","author":"SC Ugbaja","year":"2026","unstructured":"Ugbaja SC, Kumalo HM, Gqaleni N (2026) Discontinued BACE1 inhibitors in phase II\/III clinical trials and AM-6494 (preclinical) towards Alzheimer\u2019s disease therapy: repurposing through network pharmacology and molecular docking approach. Pharmaceuticals (Basel) 19:138. https:\/\/doi.org\/10.3390\/ph19010138","journal-title":"Pharmaceuticals (Basel)"},{"key":"6203_CR73","doi-asserted-by":"publisher","first-page":"8823","DOI":"10.3390\/molecules27248823","volume":"27","author":"FH Bazzari","year":"2022","unstructured":"Bazzari FH, Bazzari AH (2022) BACE1 inhibitors for Alzheimer\u2019s disease: the past, present and any future? Molecules 27:8823. https:\/\/doi.org\/10.3390\/molecules27248823","journal-title":"Molecules"},{"key":"6203_CR74","unstructured":"A Safety Study of LY2811376 Single Doses in Healthy Subjects (2009) Eli Lilly and Company. ClinicalTrials.gov Identifier: NCT00838084. https:\/\/clinicaltrials.gov\/study\/NCT00838084. (Accessed 9 November 2025)"},{"key":"6203_CR75","unstructured":"A Study of Lanabecestat (LY3314814) in Participants with Mild Alzheimer\u2019s Disease Dementia (DAYBREAK-ALZ) (2016) AstraZeneca. ClinicalTrials.gov Identifier: NCT02783573. https:\/\/clinicaltrials.gov\/study\/NCT02783573. (Accessed 10 November 2025)"},{"key":"6203_CR76","unstructured":"An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer\u2019s Disease (2012) Merck Sharp & Dohme LLC. ClinicalTrials.gov Identifier: NCT01739348. https:\/\/clinicaltrials.gov\/study\/NCT01739348. (Accessed 10 November 2025)"},{"key":"6203_CR77","unstructured":"A Study of Lanabecestat (LY3314814) in Participants with Mild Alzheimer\u2019s Disease Dementia (AMARANTH) (2016) AstraZeneca. ClinicalTrials.gov Identifier: NCT02956486. https:\/\/clinicaltrials.gov\/study\/NCT02956486. (Accessed 9 November 2025)"},{"key":"6203_CR78","unstructured":"A Study of Lanabecestat (LY3314814) in Participants with Mild Alzheimer\u2019s Disease Dementia (DAYBREAK-ALZ) (2016) AstraZeneca. ClinicalTrials.gov Identifier: NCT02783573. https:\/\/clinicaltrials.gov\/study\/NCT02783573. (Accessed 9 November 2025)"},{"key":"6203_CR79","doi-asserted-by":"publisher","first-page":"242","DOI":"10.14283\/jpad.2017.37","volume":"4","author":"C Lopez Lopez","year":"2017","unstructured":"Lopez Lopez C et al (2017) The Alzheimer\u2019s prevention initiative generation program: evaluating CNP520 efficacy in the prevention of Alzheimer\u2019s disease. J Prev Alzheimers Dis 4:242\u2013246. https:\/\/doi.org\/10.14283\/jpad.2017.37","journal-title":"J Prev Alzheimers Dis"},{"key":"6203_CR80","unstructured":"A Study of LY3314814 in Participants with Mild Alzheimer\u2019s Disease Dementia (DAYBREAK-ALZ) (2016) AstraZeneca. ClinicalTrials.gov Identifier: NCT03131453. https:\/\/clinicaltrials.gov\/study\/NCT03131453. (Accessed 9 November 2025)"},{"key":"6203_CR81","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1080\/10717544.2020.1775724","volume":"27","author":"N Lopez-Barbosa","year":"2020","unstructured":"Lopez-Barbosa N et al (2020) Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer\u2019s disease. Drug Deliv 27:864\u2013875. https:\/\/doi.org\/10.1080\/10717544.2020.1775724","journal-title":"Drug Deliv"},{"key":"6203_CR82","doi-asserted-by":"publisher","first-page":"81001","DOI":"10.18632\/oncotarget.20944","volume":"8","author":"N Huang","year":"2017","unstructured":"Huang N et al (2017) PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering A\u03b2 generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer\u2019s disease mice. Oncotarget 8:81001\u201381013. https:\/\/doi.org\/10.18632\/oncotarget.20944","journal-title":"Oncotarget"},{"key":"6203_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202203182","volume":"18","author":"X Yang","year":"2022","unstructured":"Yang X et al (2022) Intranasal delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for Alzheimer\u2019s disease therapy. Small 18:2203182. https:\/\/doi.org\/10.1002\/smll.202203182","journal-title":"Small"},{"issue":"Suppl 1","key":"6203_CR84","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.3233\/JAD-231258","volume":"101","author":"EA Watkins","year":"2024","unstructured":"Watkins EA, Vassar R (2024) BACE inhibitor clinical trials for Alzheimer\u2019s disease. J Alzheimers Dis 101(Suppl 1):S41\u2013S52. https:\/\/doi.org\/10.3233\/JAD-231258","journal-title":"J Alzheimers Dis"},{"key":"6203_CR85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fnmol.2017.00097","volume":"10","author":"R Yan","year":"2017","unstructured":"Yan R (2017) Physiological functions of the \u03b2-site amyloid precursor protein cleaving enzyme 1 and 2. Front Mol Neurosci 10:97. https:\/\/doi.org\/10.3389\/fnmol.2017.00097","journal-title":"Front Mol Neurosci"},{"key":"6203_CR86","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/1570159X19666211201095701","volume":"21","author":"H Hampel","year":"2023","unstructured":"Hampel H et al (2023) Biological mechanism-based neurology and psychiatry: a BACE1\/2 and downstream pathway model. Curr Neuropharmacol 21:31\u201353. https:\/\/doi.org\/10.2174\/1570159X19666211201095701","journal-title":"Curr Neuropharmacol"},{"key":"6203_CR87","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/cells14191506","volume":"14","author":"X Shen","year":"2025","unstructured":"Shen X, Li H, Zhang B, Li Y, Zhu Z (2025) Tau-targeted therapeutic strategies: mechanistic targets, clinical pipelines, and analysis of failures. Cells 14:1506. https:\/\/doi.org\/10.3390\/cells14191506","journal-title":"Cells"},{"key":"6203_CR88","doi-asserted-by":"publisher","first-page":"47504","DOI":"10.1021\/acsomega.2c05609","volume":"7","author":"A Akhtar","year":"2022","unstructured":"Akhtar A et al (2022) Preclinical models for Alzheimer\u2019s disease: past, present, and future approaches. ACS Omega 7:47504\u201347517. https:\/\/doi.org\/10.1021\/acsomega.2c05609","journal-title":"ACS Omega"},{"key":"6203_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70131","volume":"13","author":"MS Hossain","year":"2025","unstructured":"Hossain MS, Hussain MH (2025) Multi-target drug design in Alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations. Pharmacol Res Perspect 13:e70131. https:\/\/doi.org\/10.1002\/prp2.70131","journal-title":"Pharmacol Res Perspect"},{"key":"6203_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121721","volume":"16","author":"C Grosso","year":"2023","unstructured":"Grosso C, Silva A, Delerue-Matos C, Barroso MF (2023) Single and multitarget systems for drug delivery and detection: up-to-date strategies for brain disorders. Pharmaceuticals (Basel) 16:1721. https:\/\/doi.org\/10.3390\/ph16121721","journal-title":"Pharmaceuticals (Basel)"},{"key":"6203_CR91","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12035-021-02611-7","volume":"59","author":"M Kumar","year":"2022","unstructured":"Kumar M, Bansal N (2022) Implications of phosphoinositide 3-kinase-Akt (PI3K-Akt) pathway in the pathogenesis of Alzheimer\u2019s disease. Mol Neurobiol 59:354\u2013385. https:\/\/doi.org\/10.1007\/s12035-021-02611-7","journal-title":"Mol Neurobiol"},{"key":"6203_CR92","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.240035","volume":"14","author":"M Gyimesi","year":"2024","unstructured":"Gyimesi M, Okolicsanyi RK, Haupt LM (2024) Beyond amyloid and tau: rethinking Alzheimer\u2019s disease through less explored avenues. Open Biol 14:240035. https:\/\/doi.org\/10.1098\/rsob.240035","journal-title":"Open Biol"},{"key":"6203_CR93","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1039\/D4RA08128E","volume":"15","author":"L Liu","year":"2025","unstructured":"Liu L, He H, Du B, He Y (2025) Nanoscale drug formulations for the treatment of Alzheimer\u2019s disease progression. RSC Adv 15:4031\u20134078. https:\/\/doi.org\/10.1039\/D4RA08128E","journal-title":"RSC Adv"},{"key":"6203_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030898","volume":"15","author":"C Arbez-Gindre","year":"2023","unstructured":"Arbez-Gindre C, Steele BR, Micha-Screttas M (2023) Dendrimers in Alzheimer\u2019s disease: recent approaches in multi-targeting strategies. Pharmaceutics 15:898. https:\/\/doi.org\/10.3390\/pharmaceutics15030898","journal-title":"Pharmaceutics"},{"key":"6203_CR95","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1021\/acs.molpharmaceut.5c00329","volume":"22","author":"SV Magham","year":"2025","unstructured":"Magham SV et al (2025) Targeting GSK-3\u03b2 to modulate the Wnt pathway: a promising neuroprotective strategy for Alzheimer\u2019s disease. Mol Pharm 22:6561\u20136574. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00329","journal-title":"Mol Pharm"},{"key":"6203_CR96","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/14756366.2018.1530223","volume":"34","author":"ML Sci\u00fa","year":"2019","unstructured":"Sci\u00fa ML et al (2019) Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. J Enzyme Inhib Med Chem 34:87\u201396. https:\/\/doi.org\/10.1080\/14756366.2018.1530223","journal-title":"J Enzyme Inhib Med Chem"},{"key":"6203_CR97","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1007\/s12035-022-02923-2","volume":"59","author":"MH Yousef","year":"2022","unstructured":"Yousef MH, Salama M, El-Fawal HAN, Abdelnaser A (2022) Selective GSK3\u03b2 inhibition mediates an Nrf2-independent anti-inflammatory microglial response. Mol Neurobiol 59:5591\u20135611. https:\/\/doi.org\/10.1007\/s12035-022-02923-2","journal-title":"Mol Neurobiol"},{"key":"6203_CR98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/acsami.1c15305","volume":"14","author":"S Gupta","year":"2022","unstructured":"Gupta S, Singh V, Ganesh S, Singhal NK, Sandhir R (2022) siRNA mediated GSK3\u03b2 knockdown targets insulin signaling pathway and rescues Alzheimer\u2019s disease pathology: evidence from in vitro and in vivo studies. ACS Appl Mater Interfaces 14:69\u201393. https:\/\/doi.org\/10.1021\/acsami.1c15305","journal-title":"ACS Appl Mater Interfaces"},{"key":"6203_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106348","volume":"181","author":"H Kumar","year":"2023","unstructured":"Kumar H et al (2023) Novel therapeutic mechanism of action of metformin and its nanoformulation in Alzheimer\u2019s disease and role of AKT\/ERK\/GSK pathway. Eur J Pharm Sci 181:106348. https:\/\/doi.org\/10.1016\/j.ejps.2022.106348","journal-title":"Eur J Pharm Sci"},{"key":"6203_CR100","doi-asserted-by":"publisher","first-page":"16204","DOI":"10.1021\/acs.jafc.4c01601","volume":"72","author":"F Zhao","year":"2024","unstructured":"Zhao F et al (2024) Interaction between the neuroprotective and hyperglycemia mitigation effects of walnut-derived peptide LVRL via the Wnt3a\/\u03b2-catenin\/GSK-3\u03b2 pathway in a type 2 diabetes mellitus model. J Agric Food Chem 72:16204\u201316220. https:\/\/doi.org\/10.1021\/acs.jafc.4c01601","journal-title":"J Agric Food Chem"},{"key":"6203_CR101","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202402470R","volume":"38","author":"N Alotaiq","year":"2024","unstructured":"Alotaiq N et al (2024) Targeting GSK-3\u03b2 for adipose dysfunction and cardiovascular complications of metabolic disease: an entangled WNT\/\u03b2-catenin question. FASEB J 38:e242470R. https:\/\/doi.org\/10.1096\/fj.202402470R","journal-title":"FASEB J"},{"key":"6203_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63130-8","volume":"14","author":"A Wetzel","year":"2024","unstructured":"Wetzel A et al (2024) Dysregulated Wnt and NFAT signaling in a Parkinson\u2019s disease LRRK2 G2019S knock-in model. Sci Rep 14:12393. https:\/\/doi.org\/10.1038\/s41598-024-63130-8","journal-title":"Sci Rep"},{"key":"6203_CR103","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13287-025-04438-8","volume":"16","author":"SM Alnasser","year":"2025","unstructured":"Alnasser SM et al (2025) Pharmacological modulation of stem cell signaling pathway for therapeutic applications. Stem Cell Res Ther 16:327. https:\/\/doi.org\/10.1186\/s13287-025-04438-8","journal-title":"Stem Cell Res Ther"},{"key":"6203_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1459025","volume":"16","author":"J Pan","year":"2024","unstructured":"Pan J et al (2024) The role of PI3K signaling pathway in Alzheimer\u2019s disease. Front Aging Neurosci 16:1459025. https:\/\/doi.org\/10.3389\/fnagi.2024.1459025","journal-title":"Front Aging Neurosci"},{"key":"6203_CR105","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","volume":"367","author":"B Singh","year":"2024","unstructured":"Singh B, Day CM, Abdella S, Garg S (2024) Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release 367:402\u2013424. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.047","journal-title":"J Control Release"},{"key":"6203_CR106","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/0929867003375191","volume":"7","author":"H Sugimoto","year":"2000","unstructured":"Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y (2000) Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 7:303\u2013339. https:\/\/doi.org\/10.2174\/0929867003375191","journal-title":"Curr Med Chem"},{"key":"6203_CR107","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN et al (2004) Memantine treatment in patients with moderate to severe Alzheimer\u2019s disease already receiving donepezil. JAMA 291:317\u2013324. https:\/\/doi.org\/10.1001\/jama.291.3.317","journal-title":"JAMA"},{"key":"6203_CR108","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","volume":"17","author":"E McDade","year":"2021","unstructured":"McDade E et al (2021) The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol 17:703\u2013714. https:\/\/doi.org\/10.1038\/s41582-021-00545-1","journal-title":"Nat Rev Neurol"},{"key":"6203_CR109","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1021\/acschemneuro.5b00262","volume":"7","author":"CJ Dunning","year":"2016","unstructured":"Dunning CJ et al (2016) Direct high affinity interaction between A\u03b242 and GSK3\u03b1 stimulates hyperphosphorylation of tau. A new molecular link in Alzheimer\u2019s disease? ACS Chem Neurosci 7:161\u2013170. https:\/\/doi.org\/10.1021\/acschemneuro.5b00262","journal-title":"ACS Chem Neurosci"},{"key":"6203_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103914","volume":"29","author":"J He","year":"2024","unstructured":"He J, Tam KY (2024) Dual-target inhibitors of cholinesterase and GSK-3\u03b2 to modulate Alzheimer\u2019s disease. Drug Discov Today 29:103914. https:\/\/doi.org\/10.1016\/j.drudis.2024.103914","journal-title":"Drug Discov Today"},{"key":"6203_CR111","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1042\/BCJ20200754","volume":"478","author":"P Gupta","year":"2021","unstructured":"Gupta P et al (2021) Rivastigmine attenuates the Alzheimer\u2019s disease related protein degradation and apoptotic neuronal death signalling. Biochem J 478:1435\u20131451. https:\/\/doi.org\/10.1042\/BCJ20200754","journal-title":"Biochem J"},{"key":"6203_CR112","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jneuroim.2008.06.018","volume":"203","author":"E Nizri","year":"2008","unstructured":"Nizri E et al (2008) Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 203:12\u201322. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.06.018","journal-title":"J Neuroimmunol"},{"key":"6203_CR113","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/CIA.S129145","volume":"12","author":"N Kandiah","year":"2017","unstructured":"Kandiah N et al (2017) Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia. Clin Interv Aging 12:697\u2013707. https:\/\/doi.org\/10.2147\/CIA.S129145","journal-title":"Clin Interv Aging"},{"key":"6203_CR114","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.euroneuro.2005.06.005","volume":"16","author":"D Van Dam","year":"2006","unstructured":"Van Dam D, De Deyn PP (2006) Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 16:59\u201369. https:\/\/doi.org\/10.1016\/j.euroneuro.2005.06.005","journal-title":"Eur Neuropsychopharmacol"},{"key":"6203_CR115","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijdevneu.2017.07.006","volume":"62","author":"FK Odorcyk","year":"2017","unstructured":"Odorcyk FK et al (2017) Galantamine administration reduces reactive astrogliosis and upregulates the anti-oxidant enzyme catalase in rats submitted to neonatal hypoxia ischemia. Int J Dev Neurosci 62:15\u201324. https:\/\/doi.org\/10.1016\/j.ijdevneu.2017.07.006","journal-title":"Int J Dev Neurosci"},{"key":"6203_CR116","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/brb3.118","volume":"3","author":"JP Lopes","year":"2013","unstructured":"Lopes JP, Tarozzo G, Reggiani A, Piomelli D, Cavalli A (2013) Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav 3:67\u201374. https:\/\/doi.org\/10.1002\/brb3.118","journal-title":"Brain Behav"},{"key":"6203_CR117","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1111\/j.1460-9568.2006.04787.x","volume":"23","author":"C Volbracht","year":"2006","unstructured":"Volbracht C, Van Beek J, Zhu C, Blomgren K, Leist M (2006) Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 23:2611\u20132622. https:\/\/doi.org\/10.1111\/j.1460-9568.2006.04787.x","journal-title":"Eur J Neurosci"},{"key":"6203_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.870517","volume":"14","author":"M Shi","year":"2022","unstructured":"Shi M, Chu F, Zhu F, Zhu J (2022) Impact of anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer\u2019s disease: a focus on aducanumab and lecanemab. Front Aging Neurosci 14:870517. https:\/\/doi.org\/10.3389\/fnagi.2022.870517","journal-title":"Front Aging Neurosci"},{"key":"6203_CR119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"6203_CR120","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J (2024) Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs 38:5\u201322. https:\/\/doi.org\/10.1007\/s40259-023-00633-2","journal-title":"BioDrugs"},{"key":"6203_CR121","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","volume":"14","author":"RJ Bateman","year":"2022","unstructured":"Bateman RJ et al (2022) Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease. Alzheimers Res Ther 14:178. https:\/\/doi.org\/10.1186\/s13195-022-01110-8","journal-title":"Alzheimers Res Ther"},{"key":"6203_CR122","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/14737175.2025.2546868","volume":"25","author":"R Dodel","year":"2025","unstructured":"Dodel R, Fr\u00f6lich L (2025) Donanemab for Alzheimer\u2019s disease: from preclinical research to the clinical application. Expert Rev Neurother 25:1151\u20131163. https:\/\/doi.org\/10.1080\/14737175.2025.2546868","journal-title":"Expert Rev Neurother"},{"key":"6203_CR123","doi-asserted-by":"publisher","first-page":"e1424","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C et al (2023) Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer\u2019s disease: Lauriet. Neurology 101:e1424\u2013e1436. https:\/\/doi.org\/10.1212\/WNL.0000000000207663","journal-title":"Neurology"},{"key":"6203_CR124","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M et al (2023) TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nat Aging 3:1591\u20131601. https:\/\/doi.org\/10.1038\/s43587-023-00523-w","journal-title":"Nat Aging"},{"key":"6203_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100016","volume":"12","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane S et al (2025) Blarcamesine for the treatment of early Alzheimer\u2019s disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial. J Prev Alzheimers Dis 12:100016. https:\/\/doi.org\/10.1016\/j.tjpad.2024.100016","journal-title":"J Prev Alzheimers Dis"},{"key":"6203_CR126","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy ME et al (2016) The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci Transl Med 8:363ra150. https:\/\/doi.org\/10.1126\/scitranslmed.aad9704","journal-title":"Sci Transl Med"},{"key":"6203_CR127","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cpt.1258","volume":"105","author":"K Chris Min","year":"2019","unstructured":"Chris Min K et al (2019) Pharmacokinetics and pharmacodynamics of the BACE1 inhibitor verubecestat (MK-8931) in healthy Japanese adults: a randomized, placebo-controlled study. Clin Pharmacol Ther 105:1234\u20131243. https:\/\/doi.org\/10.1002\/cpt.1258","journal-title":"Clin Pharmacol Ther"},{"key":"6203_CR128","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neuint.2018.10.022","volume":"122","author":"D Koehler","year":"2019","unstructured":"Koehler D, Shah ZA, Williams FE (2019) The GSK3\u03b2 inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer\u2019s disease. Neurochem Int 122:31\u201337. https:\/\/doi.org\/10.1016\/j.neuint.2018.10.022","journal-title":"Neurochem Int"},{"issue":"Suppl 1","key":"6203_CR129","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.3233\/JAD-220721","volume":"94","author":"X Chen","year":"2023","unstructured":"Chen X, Jiang S, Wang R, Bao X, Li Y (2023) Neural stem cells in the treatment of Alzheimer\u2019s disease: current status, challenges, and future prospects. J Alzheimers Dis 94(Suppl 1):S173\u2013S186. https:\/\/doi.org\/10.3233\/JAD-220721","journal-title":"J Alzheimers Dis"},{"key":"6203_CR130","doi-asserted-by":"publisher","first-page":"619","DOI":"10.4103\/1673-5374.380874","volume":"19","author":"J Chang","year":"2024","unstructured":"Chang J et al (2024) Neural stem cells promote neuroplasticity: a promising therapeutic strategy for the treatment of Alzheimer\u2019s disease. Neural Regen Res 19:619\u2013628. https:\/\/doi.org\/10.4103\/1673-5374.380874","journal-title":"Neural Regen Res"},{"key":"6203_CR131","doi-asserted-by":"publisher","first-page":"18414","DOI":"10.1074\/jbc.M110.209718","volume":"286","author":"S Jimenez","year":"2011","unstructured":"Jimenez S et al (2011) Age-dependent accumulation of soluble amyloid \u03b2 (A\u03b2) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-\u03b1 (sAPP\u03b1) by modulating phosphatidylinositol 3-kinase (PI3K)\/Akt-GSK-3\u03b2 pathway in Alzheimer mouse model. J Biol Chem 286:18414\u201318425. https:\/\/doi.org\/10.1074\/jbc.M110.209718","journal-title":"J Biol Chem"},{"key":"6203_CR132","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H et al (2021) Interaction between A\u03b2 and tau in the pathogenesis of Alzheimer\u2019s disease. Int J Biol Sci 17:2181\u20132192. https:\/\/doi.org\/10.7150\/ijbs.57078","journal-title":"Int J Biol Sci"},{"key":"6203_CR133","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S1461145711000149","volume":"15","author":"CH Chen","year":"2012","unstructured":"Chen CH et al (2012) Increased NF-\u03baB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer\u2019s disease. Int J Neuropsychopharmacol 15:77\u201390. https:\/\/doi.org\/10.1017\/S1461145711000149","journal-title":"Int J Neuropsychopharmacol"},{"key":"6203_CR134","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/JCI64516","volume":"123","author":"PTT Ly","year":"2013","unstructured":"Ly PTT et al (2013) Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123:224\u2013235. https:\/\/doi.org\/10.1172\/JCI64516","journal-title":"J Clin Invest"},{"key":"6203_CR135","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14818","volume":"30","author":"J Zhao","year":"2024","unstructured":"Zhao J et al (2024) GSK3: a potential target and pending issues for treatment of Alzheimer\u2019s disease. CNS Neurosci Ther 30:e14818. https:\/\/doi.org\/10.1111\/cns.14818","journal-title":"CNS Neurosci Ther"},{"key":"6203_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1202307","volume":"11","author":"R Banerjee","year":"2023","unstructured":"Banerjee R, Gunawardena S (2023) Glycogen synthase kinase 3\u03b2 (GSK3\u03b2) and presenilin (PS) are key regulators of kinesin-1-mediated cargo motility within axons. Front Cell Dev Biol 11:1202307. https:\/\/doi.org\/10.3389\/fcell.2023.1202307","journal-title":"Front Cell Dev Biol"},{"key":"6203_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27061776","volume":"27","author":"S Subedi","year":"2022","unstructured":"Subedi S, Sasidharan S, Nag N, Saudagar P, Tripathi T (2022) Amyloid cross-seeding: mechanism, implication, and inhibition. Molecules 27:1776. https:\/\/doi.org\/10.3390\/molecules27061776","journal-title":"Molecules"},{"key":"6203_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2022.140817","volume":"1870","author":"KB Dhami","year":"2022","unstructured":"Dhami KB, Karki S, Parks A, Nichols CG, Nichols MR (2022) Development of \u03b2-sheet structure in A\u03b2 aggregation intermediates diminishes exposed hydrophobic surface area and enhances proinflammatory activity. Biochim Biophys Acta Proteins Proteom 1870:140817. https:\/\/doi.org\/10.1016\/j.bbapap.2022.140817","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"6203_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/ange.202209252","volume":"135","author":"MDC Fern\u00e1ndez-Ram\u00edrez","year":"2023","unstructured":"Fern\u00e1ndez-Ram\u00edrez MDC, Ng KK, Men\u00e9ndez M, Laurents DV, Herv\u00e1s R, Carri\u00f3n-V\u00e1zquez M (2023) Expanded conformations of monomeric tau initiate its amyloidogenesis. Angew Chem 135:e202209252. https:\/\/doi.org\/10.1002\/ange.202209252","journal-title":"Angew Chem"},{"key":"6203_CR140","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s12539-018-0307-2","volume":"11","author":"D Kumar","year":"2019","unstructured":"Kumar D, Kumar P (2019) An in silico investigation of key lysine residues and their selection for clearing off A\u03b2 and holo-A\u03b2PP through ubiquitination. Interdiscip Sci Comput Life Sci 11:584\u2013596. https:\/\/doi.org\/10.1007\/s12539-018-0307-2","journal-title":"Interdiscip Sci Comput Life Sci"},{"key":"6203_CR141","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/bi200400u","volume":"50","author":"Y Miller","year":"2011","unstructured":"Miller Y, Ma B, Nussinov R (2011) Synergistic interactions between repeats in tau protein and A\u03b2 amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry 50:5172\u20135181. https:\/\/doi.org\/10.1021\/bi200400u","journal-title":"Biochemistry"},{"key":"6203_CR142","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1021\/acs.jpclett.5b01447","volume":"6","author":"R Qi","year":"2015","unstructured":"Qi R, Luo Y, Wei G, Nussinov R, Ma B (2015) A\u03b2 \u201cstretching-and-packing\u201d cross-seeding mechanism can trigger tau protein aggregation. J Phys Chem Lett 6:3276\u20133282. https:\/\/doi.org\/10.1021\/acs.jpclett.5b01447","journal-title":"J Phys Chem Lett"},{"key":"6203_CR143","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.46924","volume":"8","author":"SL Griner","year":"2019","unstructured":"Griner SL et al (2019) Structure-based inhibitors of amyloid beta core suggest a common interface with tau. Elife 8:e46924. https:\/\/doi.org\/10.7554\/eLife.46924","journal-title":"Elife"},{"key":"6203_CR144","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT (2020) Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci 23:1183\u20131193. https:\/\/doi.org\/10.1038\/s41593-020-0687-6","journal-title":"Nat Neurosci"},{"key":"6203_CR145","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W (2023) Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther 8:248. https:\/\/doi.org\/10.1038\/s41392-023-01484-7","journal-title":"Signal Transduct Target Ther"},{"key":"6203_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1209703","volume":"16","author":"H Yu","year":"2023","unstructured":"Yu H, Xiong M, Zhang Z (2023) The role of glycogen synthase kinase 3 beta in neurodegenerative diseases. Front Mol Neurosci 16:1209703. https:\/\/doi.org\/10.3389\/fnmol.2023.1209703","journal-title":"Front Mol Neurosci"},{"key":"6203_CR147","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay6931","volume":"12","author":"F Zhang","year":"2020","unstructured":"Zhang F et al (2020) \u03b2-Amyloid redirects norepinephrine signaling to activate the pathogenic GSK3\u03b2\/tau cascade. Sci Transl Med 12:eaay6931. https:\/\/doi.org\/10.1126\/scitranslmed.aay6931","journal-title":"Sci Transl Med"},{"key":"6203_CR148","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.2174\/1568026618666180112161406","volume":"17","author":"A Rampa","year":"2018","unstructured":"Rampa A, Gobbi S, Di Martino RMC, Belluti F, Bisi A (2018) Dual BACE-1\/GSK-3\u03b2 inhibitors to combat Alzheimer\u2019s disease: a focused review. Curr Top Med Chem 17:3361\u20133369. https:\/\/doi.org\/10.2174\/1568026618666180112161406","journal-title":"Curr Top Med Chem"},{"key":"6203_CR149","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1073\/pnas.0710373105","volume":"17","author":"A Rampa","year":"2018","unstructured":"Rampa A, Gobbi S, Di Martino RMC, Belluti F, Bisi A (2018) Dual BACE-1\/GSK-3\u03b2 inhibitors to combat Alzheimer\u2019s disease: a focused review. Curr Top Med Chem 17:3361\u20133369. https:\/\/doi.org\/10.1073\/pnas.071037310","journal-title":"Curr Top Med Chem"},{"issue":"Suppl 1","key":"6203_CR150","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1471-4159.2011.07515.x","volume":"120","author":"X Sun","year":"2012","unstructured":"Sun X, Bromley-Brits K, Song W (2012) Regulation of \u03b2-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer\u2019s disease. J Neurochem 120(Suppl 1):62\u201370. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07515.x","journal-title":"J Neurochem"},{"key":"6203_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118664","volume":"1867","author":"E Lauretti","year":"2020","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D (2020) Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochimica et Biophysica Acta (BBA) 1867:118664. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118664","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"6203_CR152","doi-asserted-by":"publisher","DOI":"10.1002\/med.22045","author":"P Mayo","year":"2024","unstructured":"Mayo P, Pascual J, Crisman E, Dom\u00ednguez C, L\u00f3pez MG, Le\u00f3n R (2024) Innovative pathological network-based multitarget approaches for Alzheimer\u2019s disease treatment. Medicinal Research Reviews. https:\/\/doi.org\/10.1002\/med.22045","journal-title":"Medicinal Research Reviews"},{"key":"6203_CR153","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","volume":"19","author":"R Duara","year":"2022","unstructured":"Duara R, Barker W (2022) Heterogeneity in Alzheimer\u2019s disease diagnosis and progression rates: implications for therapeutic trials. Neurotherapeutics 19:8\u201325. https:\/\/doi.org\/10.1007\/s13311-022-01185-z","journal-title":"Neurotherapeutics"},{"key":"6203_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/ph18121797","volume":"18","author":"GD Stanciu","year":"2025","unstructured":"Stanciu GD (2025) Beyond conventional pharmacotherapy: unraveling mechanisms and advancing multi-target strategies in Alzheimer\u2019s disease. Pharmaceuticals (Basel) 18:1797. https:\/\/doi.org\/10.3390\/ph18121797","journal-title":"Pharmaceuticals (Basel)"},{"key":"6203_CR155","doi-asserted-by":"publisher","first-page":"1522223","DOI":"10.3389\/fmed.2025.1522223","volume":"12","author":"R Dhariwal","year":"2025","unstructured":"Dhariwal R et al (2025) Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology. Front Med 12:1522223. https:\/\/doi.org\/10.3389\/fmed.2025.1522223","journal-title":"Front Med"},{"key":"6203_CR156","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12088-024-01330-6","volume":"65","author":"A Jindal","year":"2025","unstructured":"Jindal A, Mainuddin KA, Ratnesh RK, Singh J (2025) Nanotechnology driven lipid and metalloid based formulations targeting blood-brain barrier (BBB) for brain tumor. Indian J Microbiol 65:92\u2013119. https:\/\/doi.org\/10.1007\/s12088-024-01330-6","journal-title":"Indian J Microbiol"},{"key":"6203_CR157","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2174\/1381612829666230707121415","volume":"29","author":"SN Sanap","year":"2023","unstructured":"Sanap SN, Bisen AC, Kedar A, Agrawal S, Bhatta RS (2023) Recent update on pharmacokinetics and drug metabolism in CNS-based drug discovery. Curr Pharm Des 29:1602\u20131616. https:\/\/doi.org\/10.2174\/1381612829666230707121415","journal-title":"Curr Pharm Des"},{"key":"6203_CR158","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/1028415X.2022.2084550","volume":"26","author":"H Lv","year":"2023","unstructured":"Lv H, Wang Y, Yang X, Ling G, Zhang P (2023) Application of curcumin nanoformulations in Alzheimer\u2019s disease: prevention, diagnosis and treatment. Nutr Neurosci 26:727\u2013742. https:\/\/doi.org\/10.1080\/1028415X.2022.2084550","journal-title":"Nutr Neurosci"},{"key":"6203_CR159","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/17425247.2025.2513440","volume":"22","author":"UD Mumtaz","year":"2025","unstructured":"Mumtaz UD, Bano A, Chauhan APS, Ali J, Khan MA (2025) Targeting Alzheimer\u2019s disease pathology: influence of nano-based drug delivery systems loaded with a combination of herbal and synthetic drugs. Expert Opin Drug Deliv 22:1155\u20131170. https:\/\/doi.org\/10.1080\/17425247.2025.2513440","journal-title":"Expert Opin Drug Deliv"},{"key":"6203_CR160","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00210-021-02096-0","volume":"394","author":"SKL Rompicherla","year":"2021","unstructured":"Rompicherla SKL, Arumugam K, Bojja SL, Kumar N, Rao CM (2021) Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 394:1737\u20131755. https:\/\/doi.org\/10.1007\/s00210-021-02096-0","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"6203_CR161","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/smll.201201068","volume":"8","author":"Y Liao","year":"2012","unstructured":"Liao Y, Chang Y, Yoshiike Y, Chang Y, Chen Y (2012) Negatively charged gold nanoparticles inhibit Alzheimer\u2019s amyloid-\u03b2 fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small 8:3631\u20133639. https:\/\/doi.org\/10.1002\/smll.201201068","journal-title":"Small"},{"key":"6203_CR162","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s13346-020-00754-z","volume":"10","author":"A Kaur","year":"2020","unstructured":"Kaur A et al (2020) Treatment of Alzheimer\u2019s disease using donepezil nanoemulsion: an intranasal approach. Drug Deliv Transl Res 10:1862\u20131875. https:\/\/doi.org\/10.1007\/s13346-020-00754-z","journal-title":"Drug Deliv Transl Res"},{"key":"6203_CR163","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1039\/D4PM00174E","volume":"1","author":"D Sonawane","year":"2024","unstructured":"Sonawane D, Pokharkar V (2024) Nose to brain targeting of the donepezil nanostructured lipid carrier in situ gel: formulation, in vitro, ex vivo, in vivo pharmacokinetic and pharmacodynamic characterization. RSC Pharm 1:820\u2013840. https:\/\/doi.org\/10.1039\/D4PM00174E","journal-title":"RSC Pharm"},{"key":"6203_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213663","volume":"154","author":"M Handa","year":"2023","unstructured":"Handa M et al (2023) Combining donepezil and memantine via mannosylated PLGA nanoparticles for intranasal delivery: characterization and preclinical studies. Biomater Adv 154:213663. https:\/\/doi.org\/10.1016\/j.bioadv.2023.213663","journal-title":"Biomater Adv"},{"key":"6203_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.106143","volume":"101","author":"T Garg","year":"2024","unstructured":"Garg T, Patel S, Yadav D, Dave V, Yadav R (2024) Convolvulus pluricaulis-lipid hybrid nanoparticles to enhance in vivo exposure and uptake of rivastigmine for Alzheimer\u2019s disease. J Drug Deliv Sci Technol 101:106143. https:\/\/doi.org\/10.1016\/j.jddst.2024.106143","journal-title":"J Drug Deliv Sci Technol"},{"key":"6203_CR166","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12951-025-03109-3","volume":"23","author":"YJ Jang","year":"2025","unstructured":"Jang YJ et al (2025) Drug delivery strategies with lipid-based nanoparticles for Alzheimer\u2019s disease treatment. J Nanobiotechnol 23:99. https:\/\/doi.org\/10.1186\/s12951-025-03109-3","journal-title":"J Nanobiotechnol"},{"key":"6203_CR167","doi-asserted-by":"publisher","first-page":"32544","DOI":"10.1021\/acsomega.5c00364","volume":"10","author":"JS Katz","year":"2025","unstructured":"Katz JS et al (2025) Overcoming the blood-brain barrier for drug delivery to the brain. ACS Omega 10:32544\u201332563. https:\/\/doi.org\/10.1021\/acsomega.5c00364","journal-title":"ACS Omega"},{"key":"6203_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113270","volume":"225","author":"S Andrade","year":"2023","unstructured":"Andrade S, Pereira MC, Loureiro JA (2023) Caffeic acid loaded into engineered lipid nanoparticles for Alzheimer\u2019s disease therapy. Colloids Surf B Biointerfaces 225:113270. https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113270","journal-title":"Colloids Surf B Biointerfaces"},{"key":"6203_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105855","volume":"98","author":"A Sonwani","year":"2024","unstructured":"Sonwani A, Pathak A, Jain K (2024) Nanocarriers-mediated nose-to-brain drug delivery: a novel approach for the management of Alzheimer\u2019s disease. J Drug Deliv Sci Technol 98:105855. https:\/\/doi.org\/10.1016\/j.jddst.2024.105855","journal-title":"J Drug Deliv Sci Technol"},{"key":"6203_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105267","volume":"91","author":"P Chakraborty","year":"2024","unstructured":"Chakraborty P, Bhattacharyya C, Sahu R, Dua TK, Kandimalla R, Dewanjee S (2024) Polymeric nanotherapeutics: an emerging therapeutic approach for the management of neurodegenerative disorders. J Drug Deliv Sci Technol 91:105267. https:\/\/doi.org\/10.1016\/j.jddst.2023.105267","journal-title":"J Drug Deliv Sci Technol"},{"key":"6203_CR171","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jtumed.2024.04.004","volume":"19","author":"YSM Elmahboub","year":"2024","unstructured":"Elmahboub YSM, Elkordy AA (2024) Polymeric nanoparticles: a promising strategy for treatment of Alzheimer\u2019s disease. J Taibah Univ Med Sci 19:549\u2013565. https:\/\/doi.org\/10.1016\/j.jtumed.2024.04.004","journal-title":"J Taibah Univ Med Sci"},{"key":"6203_CR172","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2147\/IJN.S449227","volume":"19","author":"R Oliveira Silva","year":"2024","unstructured":"Oliveira Silva R et al (2024) Donepezil-loaded nanocarriers for the treatment of Alzheimer\u2019s disease: superior efficacy of extracellular vesicles over polymeric nanoparticles. Int J Nanomedicine 19:1077\u20131096. https:\/\/doi.org\/10.2147\/IJN.S449227","journal-title":"Int J Nanomedicine"},{"key":"6203_CR173","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12035-025-05417-z","volume":"63","author":"U Kochman","year":"2026","unstructured":"Kochman U, Sitka H, Ku\u017aniar J, Czaja M, Kozubek P, Besz\u0142ej JA, Leszek J (2026) Targeted nanoparticles for drug delivery across the blood-brain barrier in early and late stages of Alzheimer\u2019s disease: a review. Mol Neurobiol 63:75. https:\/\/doi.org\/10.1007\/s12035-025-05417-z","journal-title":"Mol Neurobiol"},{"key":"6203_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12101877","volume":"12","author":"TA Patel","year":"2023","unstructured":"Patel TA et al (2023) Role of nanoparticle-conjugates and nanotheranostics in abrogating oxidative stress and ameliorating neuroinflammation. Antioxidants 12:1877. https:\/\/doi.org\/10.3390\/antiox12101877","journal-title":"Antioxidants"},{"key":"6203_CR175","doi-asserted-by":"publisher","first-page":"424","DOI":"10.7150\/ntno.86467","volume":"7","author":"M Rahman","year":"2023","unstructured":"Rahman M (2023) Magnetic resonance imaging and iron-oxide nanoparticles in the era of personalized medicine. Nanotheranostics 7:424\u2013449. https:\/\/doi.org\/10.7150\/ntno.86467","journal-title":"Nanotheranostics"},{"key":"6203_CR176","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/pharmaceutics15122666","volume":"15","author":"BS Sivamaruthi","year":"2023","unstructured":"Sivamaruthi BS, Kapoor DU, Kukkar RR, Gaur M, Elossaily GM, Prajapati BG, Chaiyasut C (2023) Mesoporous silica nanoparticles: types, synthesis, role in the treatment of Alzheimer\u2019s disease, and other applications. Pharmaceutics 15:2666. https:\/\/doi.org\/10.3390\/pharmaceutics15122666","journal-title":"Pharmaceutics"},{"key":"6203_CR177","doi-asserted-by":"publisher","first-page":"6797","DOI":"10.2147\/IJN.S434873","volume":"18","author":"Y Hu","year":"2023","unstructured":"Hu Y et al (2023) Functionalized cerium dioxide nanoparticles with antioxidative neuroprotection for Alzheimer\u2019s disease. Int J Nanomedicine 18:6797\u20136812. https:\/\/doi.org\/10.2147\/IJN.S434873","journal-title":"Int J Nanomedicine"},{"key":"6203_CR178","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1080\/1061186X.2025.2509287","volume":"33","author":"X Hu","year":"2025","unstructured":"Hu X et al (2025) Gold nanoparticles: diagnostic and therapeutic applications in neurodegenerative disorders. J Drug Target 33:1511\u20131528. https:\/\/doi.org\/10.1080\/1061186X.2025.2509287","journal-title":"J Drug Target"},{"key":"6203_CR179","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/jfb14090437","volume":"14","author":"S Jain","year":"2023","unstructured":"Jain S, Kumar M, Kumar P, Verma J, Rosenholm JM, Bansal KK, Vaidya A (2023) Lipid-polymer hybrid nanosystems: a rational fusion for advanced therapeutic delivery. J Funct Biomater 14:437. https:\/\/doi.org\/10.3390\/jfb14090437","journal-title":"J Funct Biomater"},{"key":"6203_CR180","doi-asserted-by":"publisher","first-page":"2306675","DOI":"10.1002\/advs.202306675","volume":"11","author":"R Lin","year":"2024","unstructured":"Lin R et al (2024) Hybrid membrane-coated nanoparticles for precise targeting and synergistic therapy in Alzheimer\u2019s disease. Adv Sci 11:2306675. https:\/\/doi.org\/10.1002\/advs.202306675","journal-title":"Adv Sci"},{"key":"6203_CR181","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.2174\/1381612827666210927163258","volume":"27","author":"D Jain","year":"2021","unstructured":"Jain D, Rashid MA, Ahmad FJ (2021) Recent advances in targeted drug delivery approaches using lipidic and polymeric nanocarriers for the management of Alzheimer\u2019s disease. Curr Pharm Des 27:4388\u20134403. https:\/\/doi.org\/10.2174\/1381612827666210927163258","journal-title":"Curr Pharm Des"},{"key":"6203_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.112999","volume":"221","author":"MI Teixeira","year":"2023","unstructured":"Teixeira MI, Lopes CM, Amaral MH, Costa PC (2023) Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces 221:112999. https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112999","journal-title":"Colloids Surf B Biointerfaces"},{"key":"6203_CR183","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/pharmaceutics17050661","volume":"17","author":"M Gomes","year":"2025","unstructured":"Gomes M, Ramalho MJ, Loureiro JA, Pereira MC (2025) Advancing brain targeting: cost-effective surface-modified nanoparticles for faster market entry. Pharmaceutics 17:661. https:\/\/doi.org\/10.3390\/pharmaceutics17050661","journal-title":"Pharmaceutics"},{"key":"6203_CR184","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/pharmaceutics17060706","volume":"17","author":"L Ding","year":"2025","unstructured":"Ding L, Kshirsagar P, Agrawal P, Murry DJ (2025) Crossing the blood-brain barrier: innovations in receptor- and transporter-mediated transcytosis strategies. Pharmaceutics 17:706. https:\/\/doi.org\/10.3390\/pharmaceutics17060706","journal-title":"Pharmaceutics"},{"key":"6203_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124686","volume":"665","author":"R Vargas","year":"2024","unstructured":"Vargas R et al (2024) The piper at the gates of brain: a systematic review of surface modification strategies on lipid nanoparticles to overcome the blood-brain barrier. Int J Pharm 665:124686. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124686","journal-title":"Int J Pharm"},{"key":"6203_CR186","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12938-025-01474-6","volume":"24","author":"TS Saraswathi","year":"2025","unstructured":"Saraswathi TS, Mothilal M, Bukke SPN, Thalluri C, Chettupalli AK (2025) Recent advances in potential drug nanocarriers for CNS disorders: a review. Biomed Eng Online 24:137. https:\/\/doi.org\/10.1186\/s12938-025-01474-6","journal-title":"Biomed Eng Online"},{"key":"6203_CR187","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199478","volume":"26","author":"I Ferrari","year":"2025","unstructured":"Ferrari I et al (2025) Microfluidic-based technologies for crossing the blood-brain barrier against Alzheimer\u2019s disease: novel strategies and challenges. Int J Mol Sci 26:9478. https:\/\/doi.org\/10.3390\/ijms26199478","journal-title":"Int J Mol Sci"},{"key":"6203_CR188","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1021\/acschemneuro.4c00392","volume":"15","author":"AK Mahanta","year":"2024","unstructured":"Mahanta AK, Chaulagain B, Trivedi R, Singh J (2024) Mannose-functionalized chitosan-coated PLGA nanoparticles for brain-targeted codelivery of CBD and BDNF for the treatment of Alzheimer\u2019s disease. ACS Chem Neurosci 15:4021\u20134032. https:\/\/doi.org\/10.1021\/acschemneuro.4c00392","journal-title":"ACS Chem Neurosci"},{"key":"6203_CR189","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1021\/acsnano.3c09715","volume":"18","author":"T Lei","year":"2024","unstructured":"Lei T et al (2024) Mannose-integrated nanoparticle hitchhike glucose transporter 1 recycling to overcome various barriers of oral delivery for Alzheimer\u2019s disease therapy. ACS Nano 18:3234\u20133250. https:\/\/doi.org\/10.1021\/acsnano.3c09715","journal-title":"ACS Nano"},{"key":"6203_CR190","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02826-8","volume":"37","author":"E Puris","year":"2020","unstructured":"Puris E, Gynther M, Auriola S, Huttunen KM (2020) L-type amino acid transporter 1 as a target for drug delivery. Pharm Res 37:88. https:\/\/doi.org\/10.1007\/s11095-020-02826-8","journal-title":"Pharm Res"},{"key":"6203_CR191","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2023.06.026","volume":"360","author":"EF van Vliet","year":"2023","unstructured":"van Vliet EF, Knol MJ, Schiffelers RM, Caiazzo M, Fens MHAM (2023) Levodopa-loaded nanoparticles for the treatment of Parkinson\u2019s disease. J Control Release 360:212\u2013224. https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.026","journal-title":"J Control Release"},{"key":"6203_CR192","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102237","volume":"14","author":"MS Thomsen","year":"2022","unstructured":"Thomsen MS, Johnsen KB, Kucharz K, Lauritzen M, Moos T (2022) Blood-brain barrier transport of transferrin receptor-targeted nanoparticles. Pharmaceutics 14:2237. https:\/\/doi.org\/10.3390\/pharmaceutics14102237","journal-title":"Pharmaceutics"},{"key":"6203_CR193","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/jcbfm.2009.104","volume":"29","author":"R Huang","year":"2009","unstructured":"Huang R et al (2009) Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cereb Blood Flow Metab 29:1914\u20131923. https:\/\/doi.org\/10.1038\/jcbfm.2009.104","journal-title":"J Cereb Blood Flow Metab"},{"key":"6203_CR194","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/polym14040712","volume":"14","author":"S Habib","year":"2022","unstructured":"Habib S, Singh M (2022) Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: a review. Polymers 14:712. https:\/\/doi.org\/10.3390\/polym14040712","journal-title":"Polymers"},{"key":"6203_CR195","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1096\/fj.201600827R","volume":"31","author":"Y Molino","year":"2017","unstructured":"Molino Y et al (2017) Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier. FASEB J 31:1807\u20131827. https:\/\/doi.org\/10.1096\/fj.201600827R","journal-title":"FASEB J"},{"key":"6203_CR196","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.654611","volume":"12","author":"ZT Sun","year":"2021","unstructured":"Sun ZT, Ma C, Li GJ, Zheng XY, Hao YT, Yang Y, Wang X (2021) Application of antibody fragments against A\u03b2 with emphasis on combined application with nanoparticles in Alzheimer\u2019s disease. Front Pharmacol 12:654611. https:\/\/doi.org\/10.3389\/fphar.2021.654611","journal-title":"Front Pharmacol"},{"key":"6203_CR197","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3233\/JAD-190484","volume":"70","author":"G Esquerda-Canals","year":"2019","unstructured":"Esquerda-Canals G, Roda AR, Mart\u00ed-Cl\u00faa J, Montoliu-Gaya L, Rivera-Hern\u00e1ndez G, Villegas S (2019) Treatment with scFv-h3D6 prevented neuronal loss and improved spatial memory in young 3xTg-AD mice by reducing the intracellular amyloid-\u03b2 burden. J Alzheimers Dis 70:1069\u20131091. https:\/\/doi.org\/10.3233\/JAD-190484","journal-title":"J Alzheimers Dis"},{"key":"6203_CR198","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059820","volume":"8","author":"S Dornieden","year":"2013","unstructured":"Dornieden S et al (2013) Characterization of a single-chain variable fragment recognizing a linear epitope of A\u03b2: a biotechnical tool for studies on Alzheimer\u2019s disease? PLoS ONE 8:e59820. https:\/\/doi.org\/10.1371\/journal.pone.0059820","journal-title":"PLoS ONE"},{"key":"6203_CR199","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1405423","volume":"15","author":"CE Muolokwu","year":"2024","unstructured":"Muolokwu CE, Chaulagain B, Gothwal A, Mahanta AK, Tagoe B, Lamsal B, Singh J (2024) Functionalized nanoparticles to deliver nucleic acids to the brain for the treatment of Alzheimer\u2019s disease. Front Pharmacol 15:1405423. https:\/\/doi.org\/10.3389\/fphar.2024.1405423","journal-title":"Front Pharmacol"},{"key":"6203_CR200","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13346-025-01840-w","volume":"16","author":"S Tang","year":"2026","unstructured":"Tang S, Han EL, Mitchell MJ (2026) Peptide-functionalized nanoparticles for brain-targeted therapeutics. Drug Deliv Transl Res 16:741\u2013760. https:\/\/doi.org\/10.1007\/s13346-025-01840-w","journal-title":"Drug Deliv Transl Res"},{"key":"6203_CR201","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.2147\/DDDT.S282368","volume":"14","author":"M Zhang","year":"2020","unstructured":"Zhang M, Du Y, Wang S, Chen B (2020) A review of biomimetic nanoparticle drug delivery systems based on cell membranes. Drug Des Devel Ther 14:5495\u20135503. https:\/\/doi.org\/10.2147\/DDDT.S282368","journal-title":"Drug Des Devel Ther"},{"key":"6203_CR202","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.apsb.2019.01.011","volume":"9","author":"Q Xia","year":"2019","unstructured":"Xia Q, Zhang Y, Li Z, Hou X, Feng N (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9:675\u2013689. https:\/\/doi.org\/10.1016\/j.apsb.2019.01.011","journal-title":"Acta Pharm Sin B"},{"key":"6203_CR203","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/pharmaceutics15020621","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Wei Y, Zhang C, Bi R, Qiu Y, Li Y, Hu B (2023) Cell-membrane-coated nanoparticles for targeted drug delivery to the brain for the treatment of neurological diseases. Pharmaceutics 15:621. https:\/\/doi.org\/10.3390\/pharmaceutics15020621","journal-title":"Pharmaceutics"},{"key":"6203_CR204","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3390\/pharmaceutics13122045","volume":"13","author":"L Ribovski","year":"2021","unstructured":"Ribovski L, Hamelmann NM, Paulusse JMJ (2021) Polymeric nanoparticles properties and brain delivery. Pharmaceutics 13:2045. https:\/\/doi.org\/10.3390\/pharmaceutics13122045","journal-title":"Pharmaceutics"},{"key":"6203_CR205","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/wnan.1157","volume":"4","author":"Z Amoozgar","year":"2012","unstructured":"Amoozgar Z, Yeo Y (2012) Recent advances in stealth coating of nanoparticle drug delivery systems. WIREs Nanomed Nanobiotechnol 4:219\u2013233. https:\/\/doi.org\/10.1002\/wnan.1157","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"6203_CR206","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003594","volume":"4","author":"EA Nance","year":"2012","unstructured":"Nance EA et al (2012) A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med 4:149ra119. https:\/\/doi.org\/10.1126\/scitranslmed.3003594","journal-title":"Sci Transl Med"},{"key":"6203_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15092227","volume":"15","author":"AI Visan","year":"2023","unstructured":"Visan AI, Cristescu R (2023) Polysaccharide-based coatings as drug delivery systems. Pharmaceutics 15:2227. https:\/\/doi.org\/10.3390\/pharmaceutics15092227","journal-title":"Pharmaceutics"},{"key":"6203_CR208","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.2147\/IJN.S163149","volume":"13","author":"WJ Lin","year":"2018","unstructured":"Lin WJ, Lee WC (2018) Polysaccharide-modified nanoparticles with intelligent CD44 receptor targeting ability for gene delivery. Int J Nanomedicine 13:3989\u20134002. https:\/\/doi.org\/10.2147\/IJN.S163149","journal-title":"Int J Nanomedicine"},{"key":"6203_CR209","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/pharmaceutics12111013","volume":"12","author":"AE Caprifico","year":"2020","unstructured":"Caprifico AE, Foot PJS, Polycarpou E, Calabrese G (2020) Overcoming the blood-brain barrier: functionalised chitosan nanocarriers. Pharmaceutics 12:1013. https:\/\/doi.org\/10.3390\/pharmaceutics12111013","journal-title":"Pharmaceutics"},{"key":"6203_CR210","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.7150\/thno.85419","volume":"13","author":"N Rabiee","year":"2023","unstructured":"Rabiee N, Chen S, Ahmadi S, Veedu RN (2023) Aptamer-engineered (nano)materials for theranostic applications. Theranostics 13:5183\u20135206. https:\/\/doi.org\/10.7150\/thno.85419","journal-title":"Theranostics"},{"key":"6203_CR211","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1016\/j.apsb.2024.03.034","volume":"14","author":"A Barrera-Ocampo","year":"2024","unstructured":"Barrera-Ocampo A (2024) Monoclonal antibodies and aptamers: the future therapeutics for Alzheimer\u2019s disease. Acta Pharm Sin B 14:2795\u20132814. https:\/\/doi.org\/10.1016\/j.apsb.2024.03.034","journal-title":"Acta Pharm Sin B"},{"key":"6203_CR212","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.brainresbull.2018.08.003","volume":"142","author":"B Nabi","year":"2018","unstructured":"Nabi B, Rehman S, Khan S, Baboota S, Ali J (2018) Ligand conjugation: an emerging platform for enhanced brain drug delivery. Brain Res Bull 142:384\u2013393. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.08.003","journal-title":"Brain Res Bull"},{"key":"6203_CR213","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1021\/acschemneuro.6c00245","volume":"17","author":"D Panchal","year":"2026","unstructured":"Panchal D, Solanki D, Solanki R, Yadav AK, Bhatia D, Yadav P (2026) Biomaterials and nanoparticle-based therapeutics in neurodegenerative diseases: bridging the gap between innovation and translation. ACS Chem Neurosci 17:1824\u20131869. https:\/\/doi.org\/10.1021\/acschemneuro.6c00245","journal-title":"ACS Chem Neurosci"},{"key":"6203_CR214","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/pharmaceutics1507199","volume":"15","author":"SM Ghorai","year":"2023","unstructured":"Ghorai SM, Deep A, Magoo D, Gupta C, Gupta N (2023) Cell-penetrating and targeted peptides delivery systems as potential pharmaceutical carriers for enhanced delivery across the blood-brain barrier (BBB). Pharmaceutics 15:1999. https:\/\/doi.org\/10.3390\/pharmaceutics1507199","journal-title":"Pharmaceutics"},{"key":"6203_CR215","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121643","volume":"12","author":"LB De Martini","year":"2023","unstructured":"De Martini LB, Sulmona C, Brambilla L, Rossi D (2023) Cell-penetrating peptides as valuable tools for nose-to-brain delivery of biological drugs. Cells 12:1643. https:\/\/doi.org\/10.3390\/cells12121643","journal-title":"Cells"},{"key":"6203_CR216","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","volume":"6","author":"L Chen","year":"2021","unstructured":"Chen L, Hong W, Ren W, Xu T, Qian Z, He Z (2021) Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct Target Ther 6:225. https:\/\/doi.org\/10.1038\/s41392-021-00631-2","journal-title":"Signal Transduct Target Ther"},{"key":"6203_CR217","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/17425247.2026.2659924","volume":"23","author":"N Ghosh","year":"2026","unstructured":"Ghosh N et al (2026) Biomimetic nanocarriers as advanced drug delivery strategies in neurological disorders. Expert Opin Drug Deliv 23:1249\u20131268. https:\/\/doi.org\/10.1080\/17425247.2026.2659924","journal-title":"Expert Opin Drug Deliv"},{"key":"6203_CR218","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/pharmaceutics15112623","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang Z et al (2023) Translational challenges and prospective solutions in the implementation of biomimetic delivery systems. Pharmaceutics 15:2623. https:\/\/doi.org\/10.3390\/pharmaceutics15112623","journal-title":"Pharmaceutics"},{"key":"6203_CR219","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202103347","volume":"31","author":"JD Friedl","year":"2021","unstructured":"Friedl JD, Nele V, De Rosa G, Bernkop-Schn\u00fcrch A (2021) Bioinert, stealth or interactive: how surface chemistry of nanocarriers determines their fate in vivo. Adv Funct Mater 31:2103347. https:\/\/doi.org\/10.1002\/adfm.202103347","journal-title":"Adv Funct Mater"},{"key":"6203_CR220","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s44301-025-00014-4","volume":"1","author":"F Taghavimandi","year":"2025","unstructured":"Taghavimandi F, Kim MG, Lee M, Shin K (2025) Beyond PEGylation: nanoparticle surface modulation for enhanced cancer therapy. Health Nanotechnol 1:13. https:\/\/doi.org\/10.1186\/s44301-025-00014-4","journal-title":"Health Nanotechnol"},{"key":"6203_CR221","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2019.12.034","volume":"319","author":"D Gopalan","year":"2020","unstructured":"Gopalan D, Pandey A, Udupa N, Mutalik S (2020) Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: role of surface engineered nanocarriers. J Control Release 319:183\u2013200. https:\/\/doi.org\/10.1016\/j.jconrel.2019.12.034","journal-title":"J Control Release"},{"key":"6203_CR222","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/IJN.S347187","volume":"17","author":"S Fakhri","year":"2022","unstructured":"Fakhri S, Abdian S, Zarneshan SN, Moradi SZ, Farzaei MH, Abdollahi M (2022) Nanoparticles in combating neuronal dysregulated signaling pathways: recent approaches to the nanoformulations of phytochemicals and synthetic drugs against neurodegenerative diseases. Int J Nanomedicine 17:299\u2013331. https:\/\/doi.org\/10.2147\/IJN.S347187","journal-title":"Int J Nanomedicine"},{"key":"6203_CR223","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403473","volume":"11","author":"Q Song","year":"2024","unstructured":"Song Q, Li J, Li T, Li H (2024) Nanomaterials that aid in the diagnosis and treatment of Alzheimer\u2019s disease, resolving blood-brain barrier crossing ability. Adv Sci 11:2403473. https:\/\/doi.org\/10.1002\/advs.202403473","journal-title":"Adv Sci"},{"key":"6203_CR224","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1177\/13872877251374149","volume":"107","author":"G Liu","year":"2025","unstructured":"Liu G, Sun Y (2025) Harnessing nanoparticles for Alzheimer\u2019s disease: innovations in drug delivery and pathology-specific treatments. J Alzheimers Dis 107:1374\u20131399. https:\/\/doi.org\/10.1177\/13872877251374149","journal-title":"J Alzheimers Dis"},{"key":"6203_CR225","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1662241","volume":"16","author":"AI Kareem","year":"2025","unstructured":"Kareem AI, Kapp E, Joubert J, Zou X (2025) Dual GSK3\u03b2\/SIRT1 modulators for Alzheimer\u2019s: mechanisms, drug discovery and future perspectives. Front Pharmacol 16:1662241. https:\/\/doi.org\/10.3389\/fphar.2025.1662241","journal-title":"Front Pharmacol"},{"key":"6203_CR226","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-026-02518-9","volume":"76","author":"E Manni","year":"2026","unstructured":"Manni E, Al-kuraishy HM, Eisawy R, Abdelaziz AM, Batiha G-S (2026) Reimagining GSK-3\u03b2 therapeutics in Alzheimer\u2019s disease: from inhibition to activity normalization and targeted degradation. J Mol Neurosci 76:66. https:\/\/doi.org\/10.1007\/s12031-026-02518-9","journal-title":"J Mol Neurosci"},{"key":"6203_CR227","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/0115734099270256231018072007","volume":"20","author":"M Sai Varshini","year":"2024","unstructured":"Sai Varshini M, Aishwarya Reddy R, Thaggikuppe Krishnamurthy P, Selvaraj D (2024) Rational design of dual inhibitors for Alzheimer\u2019s disease: insights from computational screening of BACE1 and GSK-3\u03b2. Curr Comput Aided Drug Des 20:998\u20131012. https:\/\/doi.org\/10.2174\/0115734099270256231018072007","journal-title":"Curr Comput Aided Drug Des"},{"key":"6203_CR228","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s12264-025-01354-y","volume":"41","author":"J He","year":"2025","unstructured":"He J, Sun S, Wang H, Ying Z, Tam KY (2025) Triple-target inhibition of cholinesterase, amyloid aggregation, and GSK3\u03b2 to ameliorate cognitive deficits and neuropathology in the triple-transgenic mouse model of Alzheimer\u2019s disease. Neurosci Bull 41:821\u2013836. https:\/\/doi.org\/10.1007\/s12264-025-01354-y","journal-title":"Neurosci Bull"},{"key":"6203_CR229","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.50","volume":"10","author":"X Jiang","year":"2020","unstructured":"Jiang X et al (2020) A natural BACE1 and GSK3\u03b2 dual inhibitor Notopterol effectively ameliorates the cognitive deficits in APP\/PS1 Alzheimer\u2019s mice by attenuating amyloid-\u03b2 and tau pathology. Clin Transl Med 10:e50. https:\/\/doi.org\/10.1002\/ctm2.50","journal-title":"Clin Transl Med"},{"key":"6203_CR230","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1021\/acschemneuro.5b00121","volume":"6","author":"F Prati","year":"2015","unstructured":"Prati F et al (2015) 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1\/GSK-3\u03b2 fragment hits against Alzheimer\u2019s disease. ACS Chem Neurosci 6:1665\u20131682. https:\/\/doi.org\/10.1021\/acschemneuro.5b00121","journal-title":"ACS Chem Neurosci"},{"key":"6203_CR231","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/acs.jmedchem.5b00894","volume":"59","author":"RMC Di Martino","year":"2016","unstructured":"Di Martino RMC et al (2016) Versatility of the curcumin scaffold: discovery of potent and balanced dual BACE-1 and GSK-3\u03b2 inhibitors. J Med Chem 59:531\u2013544. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00894","journal-title":"J Med Chem"},{"key":"6203_CR232","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/molecules28083588","volume":"28","author":"LQ Bao","year":"2023","unstructured":"Bao LQ et al (2023) Development of activity rules and chemical fragment design for in silico discovery of AChE and BACE1 dual inhibitors against Alzheimer\u2019s disease. Molecules 28:3588. https:\/\/doi.org\/10.3390\/molecules28083588","journal-title":"Molecules"},{"key":"6203_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101500","volume":"7","author":"N Jitendra Joshi","year":"2024","unstructured":"Jitendra Joshi N, Raja Sekhar Reddy A (2024) Navigating the GSK-3\u03b2 inhibitors as versatile multi-target drug ligands in Alzheimer\u2019s disease intervention \u2013 a comprehensive review. Results Chem 7:101500. https:\/\/doi.org\/10.1016\/j.rechem.2024.10150","journal-title":"Results Chem"},{"key":"6203_CR234","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16080991","volume":"16","author":"SG Londhe","year":"2024","unstructured":"Londhe SG, Walhekar V, Shenoy M, Kini SG, Scotti MT, Scotti L, Kumar D (2024) Computational and ADMET predictions of novel compounds as dual inhibitors of BuChE and GSK-3\u03b2 to combat Alzheimer\u2019s disease. Pharmaceutics 16:991. https:\/\/doi.org\/10.3390\/pharmaceutics16080991","journal-title":"Pharmaceutics"},{"key":"6203_CR235","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1766470","volume":"17","author":"V Suswidiantoro","year":"2026","unstructured":"Suswidiantoro V et al (2026) Natural compounds as multitarget agents in Alzheimer\u2019s diseases: evidence from in vivo and in vitro models. Front Pharmacol 17:1766470. https:\/\/doi.org\/10.3389\/fphar.2026.1766470","journal-title":"Front Pharmacol"},{"key":"6203_CR236","doi-asserted-by":"publisher","first-page":"1497861","DOI":"10.3389\/fphar.2025.1497861","volume":"16","author":"M Wang","year":"2025","unstructured":"Wang M, Huang W, Huang J, Luo Y, Huang N (2025) Natural bioactive compounds from herbal medicine in Alzheimer\u2019s disease: from the perspective of GSK-3\u03b2. Front Pharmacol 16:1497861. https:\/\/doi.org\/10.3389\/fphar.2025.1497861","journal-title":"Front Pharmacol"},{"key":"6203_CR237","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.70496","volume":"13","author":"G Chen","year":"2025","unstructured":"Chen G, Su Y, Chen S, Lin T, Lin X (2025) Polyphenols and Alzheimer\u2019s disease: a review on molecular and therapeutic insights with in silico support. Food Sci Nutr 13:e70496. https:\/\/doi.org\/10.1002\/fsn3.70496","journal-title":"Food Sci Nutr"},{"key":"6203_CR238","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1601712","volume":"16","author":"N Aktary","year":"2025","unstructured":"Aktary N et al (2025) Unveiling the therapeutic potential of natural products in Alzheimer\u2019s disease: insights from in vitro, in vivo, and clinical studies. Front Pharmacol 16:1601712. https:\/\/doi.org\/10.3389\/fphar.2025.1601712","journal-title":"Front Pharmacol"},{"key":"6203_CR239","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1039\/D5MD00211G","volume":"17","author":"G Rajamani","year":"2026","unstructured":"Rajamani G, Naqvi S, Sharma A (2026) Structure\u2013activity relationship of GSK-3\u03b2 inhibitors: insight into drug design for Alzheimer\u2019s disease. RSC Med Chem 17:15\u201351. https:\/\/doi.org\/10.1039\/D5MD00211G","journal-title":"RSC Med Chem"},{"key":"6203_CR240","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2174\/1389557523666221118113923","volume":"23","author":"PC Prado","year":"2023","unstructured":"Prado PC, Lima JA, Hamerski L, Renn\u00f3 MN (2023) Natural products with BACE1 and GSK3\u03b2 inhibitory activity. Mini Rev Med Chem 23:881\u2013895. https:\/\/doi.org\/10.2174\/1389557523666221118113923","journal-title":"Mini Rev Med Chem"},{"key":"6203_CR241","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1021\/acs.jmedchem.0c00931","volume":"64","author":"A De Simone","year":"2021","unstructured":"De Simone A, Tumiatti V, Andrisano V, Milelli A (2021) Glycogen synthase kinase 3\u03b2: a new gold rush in anti-Alzheimer\u2019s disease multitarget drug discovery? J Med Chem 64:26\u201341. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00931","journal-title":"J Med Chem"},{"key":"6203_CR242","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25153337","volume":"25","author":"A Zag\u00f3rska","year":"2020","unstructured":"Zag\u00f3rska A, Jaromin A (2020) Perspectives for new and more efficient multifunctional ligands for Alzheimer\u2019s disease therapy. Molecules 25:3337. https:\/\/doi.org\/10.3390\/molecules25153337","journal-title":"Molecules"},{"key":"6203_CR243","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.apsb.2024.11.016","volume":"15","author":"P Ashwini","year":"2025","unstructured":"Ashwini P, Subhash B, Amol M, Kumar D, Atmaram P, Ravindra K (2025) Comprehensive investigation of multiple targets in the development of newer drugs for Alzheimer\u2019s disease. Acta Pharm Sin B 15:1281\u20131310. https:\/\/doi.org\/10.1016\/j.apsb.2024.11.016","journal-title":"Acta Pharm Sin B"},{"key":"6203_CR244","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/nat.2019.0812","volume":"29","author":"ZM Liang","year":"2019","unstructured":"Liang ZM et al (2019) The BACE1-specific DNA aptamer A1 rescues amyloid-\u03b2 pathology and behavioral deficits in a mouse model of Alzheimer\u2019s disease. Nucleic Acid Ther 29:359\u2013366. https:\/\/doi.org\/10.1089\/nat.2019.0812","journal-title":"Nucleic Acid Ther"},{"key":"6203_CR245","doi-asserted-by":"publisher","first-page":"2203182","DOI":"10.1002\/smll.202203182","volume":"18","author":"X Yang","year":"2022","unstructured":"Yang X et al (2022) Intranasal delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for Alzheimer\u2019s disease therapy. Small 18:2203182. https:\/\/doi.org\/10.1002\/smll.20220318","journal-title":"Small"},{"key":"6203_CR246","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.2147\/IJN.S506793","volume":"20","author":"C Sun","year":"2025","unstructured":"Sun C et al (2025) Intranasal delivery of BACE1 siRNA and berberine via engineered stem cell exosomes for the treatment of Alzheimer\u2019s disease. Int J Nanomedicine 20:5873\u20135891. https:\/\/doi.org\/10.2147\/IJN.S506793","journal-title":"Int J Nanomedicine"},{"key":"6203_CR247","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","volume":"279","author":"P Wang","year":"2018","unstructured":"Wang P et al (2018) Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease. J Control Release 279:220\u2013233. https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.034","journal-title":"J Control Release"},{"key":"6203_CR248","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc7031","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y et al (2020) Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy. Sci Adv 6:eabc7031. https:\/\/doi.org\/10.1126\/sciadv.abc7031","journal-title":"Sci Adv"},{"key":"6203_CR249","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","volume":"152","author":"G Rassu","year":"2017","unstructured":"Rassu G, Soddu E, Posadino AM, Pintus G, Sarmento B, Giunchedi P, Gavini E (2017) Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer\u2019s therapy. Colloids Surf B Biointerfaces 152:296\u2013301. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.01.031","journal-title":"Colloids Surf B Biointerfaces"},{"key":"6203_CR250","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.15","volume":"4","author":"R Shyam","year":"2015","unstructured":"Shyam R, Ren Y, Lee J, Braunstein KE, Mao HQ, Wong PC (2015) Intraventricular delivery of siRNA nanoparticles to the central nervous system. Mol Ther Nucleic Acids 4:e242. https:\/\/doi.org\/10.1038\/mtna.2015.15","journal-title":"Mol Ther Nucleic Acids"},{"key":"6203_CR251","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00503-7","volume":"14","author":"Z Li","year":"2025","unstructured":"Li Z et al (2025) Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer\u2019s disease. Transl Neurodegener 14:41. https:\/\/doi.org\/10.1186\/s40035-025-00503-7","journal-title":"Transl Neurodegener"},{"key":"6203_CR252","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1039\/D5NA00993F","volume":"8","author":"X Yuan","year":"2026","unstructured":"Yuan X, Tang Q, Wang T (2026) Nanotechnology-based targeted delivery strategies for the treatment of Alzheimer\u2019s disease. Nanoscale Adv 8:2195\u20132214. https:\/\/doi.org\/10.1039\/D5NA00993F","journal-title":"Nanoscale Adv"},{"key":"6203_CR253","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/biomedicines11061752","volume":"11","author":"SN Mir Najib Ullah","year":"2023","unstructured":"Mir Najib Ullah SN et al (2023) Nanomedicine in the management of Alzheimer\u2019s disease: state-of-the-art. Biomedicines 11:1752. https:\/\/doi.org\/10.3390\/biomedicines11061752","journal-title":"Biomedicines"},{"key":"6203_CR254","doi-asserted-by":"publisher","first-page":"53633","DOI":"10.1021\/acsomega.4c04887","volume":"10","author":"TE Tutubala","year":"2025","unstructured":"Tutubala TE, Egunlusi AO, Fisher D, Dube A, Joubert J (2025) Nanomedicine solutions for Alzheimer\u2019s disease: a critical review of therapeutic nanoparticle strategies. ACS Omega 10:53633\u201353657. https:\/\/doi.org\/10.1021\/acsomega.4c04887","journal-title":"ACS Omega"},{"key":"6203_CR255","doi-asserted-by":"publisher","first-page":"13039","DOI":"10.2147\/IJN.S554821","volume":"20","author":"Y Herdiana","year":"2025","unstructured":"Herdiana Y (2025) Bridging the gap: the role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems. Int J Nanomedicine 20:13039\u201313053. https:\/\/doi.org\/10.2147\/IJN.S554821","journal-title":"Int J Nanomedicine"},{"key":"6203_CR256","doi-asserted-by":"publisher","DOI":"10.3390\/nano8050311","volume":"8","author":"S M\u00fclhopt","year":"2018","unstructured":"M\u00fclhopt S et al (2018) Characterization of nanoparticle batch-to-batch variability. Nanomaterials 8:311. https:\/\/doi.org\/10.3390\/nano8050311","journal-title":"Nanomaterials"},{"key":"6203_CR257","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/pharmaceutics12020146","volume":"12","author":"EB Souto","year":"2020","unstructured":"Souto EB et al (2020) Nanopharmaceutics: Part I\u2014Clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in the EU. Pharmaceutics 12:146. https:\/\/doi.org\/10.3390\/pharmaceutics12020146","journal-title":"Pharmaceutics"},{"key":"6203_CR258","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1021\/acsnano.4c09566","volume":"19","author":"R Tenchov","year":"2025","unstructured":"Tenchov R et al (2025) Transforming medicine: cutting-edge applications of nanoscale materials in drug delivery. ACS Nano 19:4011\u20134038. https:\/\/doi.org\/10.1021\/acsnano.4c09566","journal-title":"ACS Nano"},{"key":"6203_CR259","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.2147\/IJN.S231477","volume":"15","author":"A Karabasz","year":"2020","unstructured":"Karabasz A, Bzowska M, Szczepanowicz K (2020) Biomedical applications of multifunctional polymeric nanocarriers: a review of current literature. Int J Nanomedicine 15:8673\u20138696. https:\/\/doi.org\/10.2147\/IJN.S231477","journal-title":"Int J Nanomedicine"},{"key":"6203_CR260","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12951-025-03442-7","volume":"23","author":"Y Shi","year":"2025","unstructured":"Shi Y, Li X, Li Z, Sun J, Gao T, Wei G, Guo Q (2025) Nano-formulations in disease therapy: designs, advances, challenges, and future directions. J Nanobiotechnol 23:396. https:\/\/doi.org\/10.1186\/s12951-025-03442-7","journal-title":"J Nanobiotechnol"},{"key":"6203_CR261","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2217\/nnm-2017-0039","volume":"12","author":"V Agrahari","year":"2017","unstructured":"Agrahari V, Hiremath P (2017) Challenges associated and approaches for successful translation of nanomedicines into commercial products. Nanomedicine (Lond) 12:819\u2013823. https:\/\/doi.org\/10.2217\/nnm-2017-0039","journal-title":"Nanomedicine (Lond)"},{"key":"6203_CR262","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.327","volume":"4","author":"L Xuan","year":"2023","unstructured":"Xuan L, Ju Z, Skonieczna M, Zhou P, Huang R (2023) Nanoparticles-induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. MedComm (2020) 4:e327. https:\/\/doi.org\/10.1002\/mco2.327","journal-title":"MedComm (2020)"},{"key":"6203_CR263","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2026.100117","volume":"4","author":"GI Edo","year":"2026","unstructured":"Edo GI et al (2026) Toxicity of nanostructures in drug delivery applications. Pharm Sci Adv 4:100117. https:\/\/doi.org\/10.1016\/j.pscia.2026.100117","journal-title":"Pharm Sci Adv"},{"key":"6203_CR264","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-024-04118-1","volume":"19","author":"U Havelikar","year":"2024","unstructured":"Havelikar U, Ghorpade KB, Kumar A, Patel A, Singh M, Banjare N, Gupta PN (2024) Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines. Discover Nano 19:165. https:\/\/doi.org\/10.1186\/s11671-024-04118-1","journal-title":"Discover Nano"},{"key":"6203_CR265","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF et al (2019) Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N Engl J Med 380:1408\u20131420. https:\/\/doi.org\/10.1056\/NEJMoa1812840","journal-title":"N Engl J Med"},{"key":"6203_CR266","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2018.94","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard A (2018) BACE failures lower AD expectations, again. Nat Rev Drug Discov 17:385. https:\/\/doi.org\/10.1038\/nrd.2018.94","journal-title":"Nat Rev Drug Discov"},{"key":"6203_CR267","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120807","volume":"605","author":"MC Operti","year":"2021","unstructured":"Operti MC, Bernhardt A, Grimm S, Engel A, Figdor CG, Tagit O (2021) PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up. Int J Pharm 605:120807. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120807","journal-title":"Int J Pharm"},{"key":"6203_CR268","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/technologies13030094","volume":"13","author":"N Sharmile","year":"2025","unstructured":"Sharmile N, Chowdhury RR, Desai S (2025) A comprehensive review of quality control and reliability research in micro\u2013nano technology. Technologies 13:94. https:\/\/doi.org\/10.3390\/technologies13030094","journal-title":"Technologies"},{"key":"6203_CR269","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.3390\/pharmaceutics14091940","volume":"14","author":"K Osouli-Bostanabad","year":"2022","unstructured":"Osouli-Bostanabad K, Puliga S, Serrano DR, Bucchi A, Halbert G, Lalatsa A (2022) Microfluidic manufacture of lipid-based nanomedicines Pharmaceutics 14:1940. https:\/\/doi.org\/10.3390\/pharmaceutics14091940","journal-title":"Microfluidic manufacture of lipid-based nanomedicines Pharmaceutics"},{"key":"6203_CR270","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306675","volume":"11","author":"R Lin","year":"2024","unstructured":"Lin R et al (2024) Hybrid membrane-coated nanoparticles for precise targeting and synergistic therapy in Alzheimer\u2019s disease. Adv Sci 11:2306675. https:\/\/doi.org\/10.1002\/advs.202306675","journal-title":"Adv Sci"},{"key":"6203_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2024.100266","volume":"8","author":"AB Buya","year":"2024","unstructured":"Buya AB, Mahlangu P, Witika BA (2024) From lab to industrial development of lipid nanocarriers using quality by design approach. Int J Pharm X 8:100266. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100266","journal-title":"Int J Pharm X"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06203-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06203-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06203-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:56:30Z","timestamp":1789944990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06203-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":271,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6203"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06203-1","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"909"}}